

18 FEB 2005

PCT/EP 03/09291

REC'D 14 OCT 2003

WIPO PCT

PA 1057814

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

August 27, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/404,928

FILING DATE: August 22, 2002

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. SWAIN
Certifying Officer

6040428 . 082202

Provisional Application For Patent Cover Sheet

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 C.F.R. § 1.53(c).

Express Mail Label No

INVENTOR(S)

Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)
Lidia	Ivanova	Zürich, Switzerland
Philippe	Saudan	Pfungen, Switzerland
Wolfgang A.	Renner	Kilchberg, Switzerland

☐ Additional inventors are being named on the ___ separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 Characters Maximum)

GENE EXPRESSION SYSTEM

CORRESPONDENCE ADDRESS

Direct all correspondence to

Place Customer Number

☒ Customer number 26111


Bar Code Label here

Type Customer Number here



26111

PATENT TRADEMARK OFFICE

OR

☐ Firm or Individual Name

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Address

1100 New York Avenue, Suite 600

Address

City

Washington

State

D.C.

ZIP

20005

Country

USA

Telephone

202-371-2600

Fax

202-371-2540

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification Number of pages 74
☐ CD(s), Number _____

☒ Drawing(s) Number of sheets: 20
☐ Other (specify) _____

☒ Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)

☐ Applicant claims small entity status. See 37 CFR 1.27.

☒ A check or money order is enclosed to cover the filing fees
Filing Fee
Amount (\$)
☒ The Commissioner is hereby authorized to charge filing fees or credit any overpayments to Deposit Account Number: 19-0036.

160.00

☐ Payment by credit card. Form PTO-2038 is attached.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No

☐ Yes, the name of the U.S. Government agency and the Government contract number are _____

Respectfully submitted,

Signature: Frank R. CottinghamTyped or Printed Name: Frank R. CottinghamTelephone: 202-371-2600Date: 8/22/02Registration No. 50,437 (if appropriate)Docket Number: 1700.0370000/JAG/EEF/FRC

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT



**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW

Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmund
Tracy-Gene G. Durkin
Michael A. Cambala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Undia E. Alcom
Robert C. Millung
Lawrence B. Burgalsky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffery T. Helvey
Heidi L. Kraus
Crystal D. Sayles
Edward W. Vee
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II
Eldora Ellison Floyd
W. Russell Swindell

Thomas C. Hala
Brian J. Del Buono
Virgil Lee Beaton
Reginald D. Lucas
Katherine W. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Uhler
Rae Lynn Prengaman
Jane Shershenovich
Lawrence J. Carroll
George S. Seidmeyer
Rodney G. Maze

Registered Patent Agents*
Karen R. Markowicz
Andrea J. Kamaga
Nancy J. Leith
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Mahvenko
Mary B. Tung
Kathrina Y. Pei
Bryan I. Skelton
Robert A. Schwartzman
Jason D. Eisenberg
John J. Figueroa

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III
Lisa A. Dunner

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas
*Practice Limited to
Federal Agencies

PTO
U.S.
08/22/02

August 22, 2002

WRITER'S DIRECT NUMBER:
(202) 371-2615
INTERNET ADDRESS:
FRANKC@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Box Provisional Application

Re: U.S. Provisional Patent Application
Appl. No. To be assigned; Filed: Herewith
For: **GENE EXPRESSION SYSTEM**
Inventors: IVANOVA *et al.*
Our Ref: 1700.0370000/JAG/EEF/FRC

Sir:

The following documents are being submitted under 37 C.F.R. § 1.53(c) herewith for appropriate action by the U.S. Patent and Trademark Office:

1. PTO Fee Transmittal (Form PTO/SB/17);
2. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3);
3. A Provisional Application for Patent Cover Sheet;
4. Application Data Sheet (37 C.F.R. § 1.76);
5. U.S. Provisional Patent Application entitled:

GENE EXPRESSION SYSTEM

and naming as inventors:

LIDIA IVANOVA
PHILIPPE SAUDAN
WOLFGANG A. RENNER

Commissioner for Patents

August 22, 2002

Page 2

the application consisting of:

- a. A specification containing 74 total pages:
 - (i) 57 pages of description prior to any claims;
 - (ii) 16 pages of claims (109 claims); and
 - (iii) a one page abstract;
 - b. 20 sheets of drawings: (Figures 1, 2A, 2B, 2C, 2D, 3, 4, 5, 6, 7, 8A, 8B, 8C, 8D, 8E, 9A, 9B, 9C, 9D, and 9E);
6. Our check no. **36383** in the amount of **\$160.00** to cover the filing fee; and
 7. Two (2) return postcards.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and returned as soon as possible.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham

Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

FRC/pcd
Encls.

SKGF_DC1 48358 1

601-711-1111 . 032202

Approved for use through 10/31/2002 PTO/SB/17 (10-01)
 Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
 OMB 0651-0032
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision

Complete if known

TOTAL AMOUNT OF PAYMENT	(\$160.00)	Application Number	To be assigned
		Filing Date	Herewith
		First Named Inventor	Lidia Ivanova
		Examiner Name	N/A
		Group Art Unit	N/A
		Attorney Docket No.	1700.0370000/JAG/EEF/FRC

METHOD OF PAYMENT (check one)				FEE CALCULATION (continued)																																																																																							
1. <input type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to Deposit Account Number: 19-0036 Deposit Account Name: Sterne, Kessler, Goldstein & Fox P L L C <input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17 <input type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27				3. ADDITIONAL FEES Large Entity Small Entity Fee Code Fee (\$) Fee Code Fee (\$) Fee Description Fee paid																																																																																							
2. <input checked="" type="checkbox"/> Payment Enclosed <input checked="" type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input checked="" type="checkbox"/> Other* <small>*Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036</small>				105 130 205 65 Surcharge - late filing fee or oath 127 50 227 25 Surcharge - late provisional filing fee or cover sheet 139 130 139 130 Non-English specification 147 2,520 147 2,520 For filing a request for <i>ex parte</i> reexamination 112 920* 112 920* Requesting publication of SIR prior to Examiner action 113 1,840* 113 1,840* Requesting publication of SIR after Examiner action 115 110 215 55 Extension for reply within first month 116 400 216 200 Extension for reply within second month 117 920 217 460 Extension for reply within third month 118 1,440 218 720 Extension for reply within fourth month 128 1,980 228 980 Extension for reply within fifth month 119 320 219 160 Notice of Appeal 120 320 220 160 Filing a brief in support of an appeal 121 280 221 140 Request for oral hearing 138 1,510 138 1,510 Petition to institute a public use proceeding 140 110 240 55 Petition to revive - unavoidable 141 1,280 241 640 Petition to revive - unintentional 142 1,280 242 640 Utility issue fee (or reissue) 143 460 243 230 Design issue fee 144 620 244 310 Plant issue fee 122 130 122 130 Petitions to the Commissioner 123 130 123 130 Petitions related to provisional applications 126 180 126 180 Submission of Information Disclosure Stmt 581 40 481 40 Recording each patent assignment per property (times number of properties) 146 740 246 370 Filing a submission after final rejection (37 CFR 1.129(a)) 149 740 249 370 For each additional invention to be examined (37 CFR 1.129(b)) 179 740 279 370 Request for Continued Examination (RCE) 169 900 169 900 Request for expedited examination of a design application Other fee (specify) Other fee (specify)																																																																																							
FEE CALCULATION I. BASIC FILING FEE <table border="1"> <thead> <tr> <th>Large Fee Code</th> <th>Entity Fee (\$)</th> <th>Small Fee Code</th> <th>Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>101</td> <td>740</td> <td>201</td> <td>370</td> <td>Utility filing fee</td> <td></td> </tr> <tr> <td>106</td> <td>330</td> <td>206</td> <td>165</td> <td>Design filing fee</td> <td></td> </tr> <tr> <td>107</td> <td>510</td> <td>207</td> <td>255</td> <td>Plant filing fee</td> <td></td> </tr> <tr> <td>108</td> <td>740</td> <td>208</td> <td>370</td> <td>Reissue filing fee</td> <td></td> </tr> <tr> <td>114</td> <td>180</td> <td>214</td> <td>80</td> <td>Provisional filing fee</td> <td>160.00</td> </tr> <tr> <td colspan="5">SUBTOTAL (1) (\$)</td> <td>160.00</td> </tr> </tbody> </table>				Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid	101	740	201	370	Utility filing fee		106	330	206	165	Design filing fee		107	510	207	255	Plant filing fee		108	740	208	370	Reissue filing fee		114	180	214	80	Provisional filing fee	160.00	SUBTOTAL (1) (\$)					160.00	II. EXTRA CLAIM FEES <table border="1"> <thead> <tr> <th>Large Fee Code</th> <th>Entity Fee (\$)</th> <th>Small Fee Code</th> <th>Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>103</td> <td>18</td> <td>203</td> <td>9</td> <td>Claims in excess of 20</td> <td></td> </tr> <tr> <td>102</td> <td>84</td> <td>202</td> <td>42</td> <td>Independent claims in excess of 3</td> <td></td> </tr> <tr> <td>104</td> <td>280</td> <td>204</td> <td>140</td> <td>Multiple dependent claim</td> <td></td> </tr> <tr> <td>108</td> <td>84</td> <td>208</td> <td>42</td> <td>**Reissue independent claims over original patent</td> <td></td> </tr> <tr> <td>110</td> <td>18</td> <td>210</td> <td>9</td> <td>**Reissue claims in excess of 20 and over original patent</td> <td></td> </tr> <tr> <td colspan="5">SUBTOTAL (2) (\$)</td> <td></td> </tr> </tbody> </table>				Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid	103	18	203	9	Claims in excess of 20		102	84	202	42	Independent claims in excess of 3		104	280	204	140	Multiple dependent claim		108	84	208	42	**Reissue independent claims over original patent		110	18	210	9	**Reissue claims in excess of 20 and over original patent		SUBTOTAL (2) (\$)					
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid																																																																																						
101	740	201	370	Utility filing fee																																																																																							
106	330	206	165	Design filing fee																																																																																							
107	510	207	255	Plant filing fee																																																																																							
108	740	208	370	Reissue filing fee																																																																																							
114	180	214	80	Provisional filing fee	160.00																																																																																						
SUBTOTAL (1) (\$)					160.00																																																																																						
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid																																																																																						
103	18	203	9	Claims in excess of 20																																																																																							
102	84	202	42	Independent claims in excess of 3																																																																																							
104	280	204	140	Multiple dependent claim																																																																																							
108	84	208	42	**Reissue independent claims over original patent																																																																																							
110	18	210	9	**Reissue claims in excess of 20 and over original patent																																																																																							
SUBTOTAL (2) (\$)																																																																																											
** or number previously paid, if greater, For Reissues, see above				SUBTOTAL (3) (\$)																																																																																							

SUBMITTED BY		Complete (if applicable)			
Name (Print/Type)	Frank R. Cottingham	Registration No. (Attorney/Agent)	50,437	Telephone	202-371-2600
Signature	<i>Frank R. Cottingham</i>	Date	8/22/02		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.
 Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SKGF Rev. 6/11/02 mnc #48362v1-SKGF_DC1>-1700.0370000-ProvApp_feesht-FRC-pcd.wpd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

IVANOVA *et al.*

Appl. No. To be assigned

Filed: Herewith

For: **GENE EXPRESSION SYSTEM**

Confirmation No. To be assigned

Art Unit: N/A

Examiner: N/A

Atty. Docket: 1700.0370000/JAG/EEF/FRC

**Authorization To Treat A Reply As Incorporating An Extension Of
Time Under 37 C.F.R. § 1.136(a)(3)**

Commissioner for Patents
Washington, D.C. 20231

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham

Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

Date: 8/22/02
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

::ODMA\MHODMA\SKGF_DC1;48361;1

INVENTOR INFORMATION

60404928.082202

Inventor One Given Name:: Lidia
Family Name:: Ivanova
Postal Address Line One:: Bachmattstrasse 58
City:: CH-8048 Zurich
Country:: Switzerland
City of Residence:: Zurich
Country of Residence:: Switzerland
Citizenship Country:: USA
Inventor Two Given Name:: Philippe
Family Name:: Saudan
Postal Address Line One:: Durrenrainstrasse 20
City:: CH-8422 Pfungen
Country:: Switzerland
City of Residence:: Pfungen
Country of Residence:: Switzerland
Citizenship Country:: Switzerland
Inventor Three Given Name:: Wolfgang A
Family Name:: Renner
Postal Address Line One:: Grenzsteig 9
City:: 8802 Kilchberg
Country:: Switzerland
City of Residence:: Kilchberg
Country of Residence:: Switzerland
Citizenship Country:: Switzerland

APPLICATION INFORMATION

Title Line One:: GENE EXPRESSION SYSTEM
Total Drawing Sheets:: 20
Formal Drawings?:: No
Application Type:: Provisional
Docket Number:: 1700.0370000
Secrecy Order in Parent Appl.?:: No

REPRESENTATIVE INFORMATION

Representative Customer Number:: 26111
Source:: PrintEFS Version 1.0.1

GENE EXPRESSION SYSTEM

BACKGROUND OF THE INVENTION

Field of the Invention

- [0001] The present invention relates to compositions and methods for the production of polypeptides and/or untranslated RNA molecules in host cells. The invention provides nucleic acid molecules, expression systems, host cells, methods and kits that are useful for the production of polypeptides and/or untranslated RNA molecules. In a preferred embodiment, the invention allows regulated and/or inducible expression of a nucleotide sequence of interest in a host cell.

Related Art

- [0002] Process development for biopharmaceuticals is influenced by product quality and economy of the manufacturing process. The economic production of recombinant proteins in mammalian cells is dependent on the selection of the producing cell lines. The classical approach is the use of stable expression systems. These systems are based on chromosomal integration of an expression plasmid into the genome of the host cell.
- [0003] An alternative to stable expression systems is transient gene expression. For example, transient gene expression in, *e.g.*, mammalian cells at reactor scale is becoming increasingly important for the rapid production of recombinant proteins. Large scale applications of transient expression systems for recombinant protein production have been reported using COS, HEK 293 and BHK21 cells (Blasey et al., 1996, *Cytotechnology*, 18, 138-192; Jordan et al., 1998, *Cytotechnology*, 26, 39-47; Wurm and Bernard, 1999, *Curr Opin Biotechnol* 10, 156-159; Meissner et al., 2001, *Biotechnol and Bioeng*, 75, 2, 197-203).
- [0004] Transient expression can be performed by infection (using, *e.g.*, viral vectors) or by transfection of the appropriate vector. Transfection can be

performed with either a non-replicating or a replicating DNA vector or with a virus derived RNA vector.

[0005] A variety of virus vectors for expression in higher eukaryotic cells have been developed by using recombinant DNA technology and introducing genes of interest into virus genomes. The initial viruses used in vector development were DNA viruses such as Adeno-associated viruses or Poxviruses as well as RNA viruses replicating through DNA intermediates such as Retroviruses.

[0006] Episomal replicating vectors provide certain advantages over classical expression systems. Some DNA viruses, such as Adeno-, Papilloma-, Polyoma-, Hepadna-, and Herpesviruses, do not normally integrate into the host genome, but replicate episomally (extrachromosomally) in the nucleus of a host cells such as in a mammalian host cell. This process may involve both virus trans-acting factors and the host cell replication machinery. Episomal replicating vectors derived from these viruses generally contain a replication origin and at least one viral protein, *e.g.*, an initiator protein. Examples of such initiator proteins are large T-antigen for SV40, E1/E2 for BPV, and EBNA-1 for EBV.

[0007] Some host factors are able to recognize viral origins of replication and initiate replication. For example human S/MAR (scaffold/matrix attached region from the human interferon-beta gene) is able to maintain the episomal replication of a vector containing SV 40 origin of replication. On the other hand certain viral origins of replication (ORI) are recognized by corresponding specific virally-encoded proteins. For example, SV40 or polyoma virus ORI is recognized by large T antigen, BPV (Bovine papilloma virus) ORI is recognized by E1/E2 complex, EBV (Epstein-Barr virus) ORI is recognized by EBNA1 protein, and yeast origin of replication (ARS element) is recognized by ORE (origin recognition element) replication (Bode et al., 2001 Gene Ther Mol Biol, v6, 33-46).

[0008] The double strand DNA genome of Epstein-Barr virus EBV (165 kb) is maintained in the latently infected cells as a large circular episome. Amplification of this episome is mediated by a cis-acting sequence such as the

origin of replication (OriP), and one of the viral proteins, the Epstein-Barr viral nuclear antigen 1 (EBNA1). In a minimal system the presence of both OriP (1.8 kb region) and EBNA-1 is sufficient for replication and stabilization of recombinant plasmids. The exact function of EBNA-1 is still not clear, although the protein has a DNA binding domain. Generally EBNA-1 is involved in plasmid maintenance after completion of the synthesis and in plasmid segregation by dividing cells during proliferation. The OriP region is recognized also directly by the cellular DNA synthesizing machinery and is replicated during the cell cycle.

[0009] Other gene expression systems are based on alphaviruses (Lundstrom, K., *Curr. Opin. Biotechnol.* 8:578-582 (1997)). Several members of the alphavirus family, e.g., Sindbis virus (Xiong, C. *et al.*, *Science* 243:1188-1191 (1989); Schlesinger, S., *Trends Biotechnol.* 11:18-22 (1993)), SFV (Liljeström, P. & Garoff, H., *Bio/Technology* 9:1356-1361 (1991)) and others (Davis, N.L. *et al.*, *Virology* 171:189-204 (1989)) have received considerable attention for the use as virus-based expression vectors for a variety of different proteins (Lundstrom, K., *Curr. Opin. Biotechnol.* 8:578-582 (1997); Liljeström, P., *Curr. Opin. Biotechnol.* 5:495-500 (1994)).

[0010] Alphaviruses are positive stranded RNA viruses which replicate their genomic RNA entirely in the cytoplasm of the infected cell and without a DNA intermediate (Strauss, J. and Strauss, E., *Microbiol. Rev.* 58:491-562 (1994)). The concept that alphaviruses can be developed as expression vectors was first established nearly ten years ago (Xiong, C. *et al.*, *Science* 243:1188-1191 (1989)). Since then, several improvements have made the use of these RNA replicons as expression vectors more practical (Lundstrom, K., *Curr. Opin. Biotechnol.* 8:578-582 (1997)).

[0011] DNA vectors have been developed for both Sindbis virus (Herweijer, H. *et al.*, *Hum. Gene Ther.* 6:1495-1501 (1995); Dubensky, T.W. *et al.*, *J. Virol.* 70:508-519 (1996)) and SFV (Berglund, P. *et al.*, *Trends Biotechnol.* 14:130-134 (1996)). Eukaryotic promoters are introduced in these vectors upstream from the alphavirus replicase gene (consisting of the four non-structural protein genes (nsP1-4)), which are translated as one or two

polyproteins which are then proteolytically cleaved. DNA is transcribed into RNA from the recombinant eukaryotic promoter in the nucleus and transported to the cytoplasm, where the replicase catalyzes the replication of the alphavirus RNA molecule as during normal replication of the alphavirus RNA molecule (Strauss, J. and Strauss, E., *Microbiol. Rev.* 58:491-562 (1994)). Only transient expression of heterologous sequences has been possible until recently due to the cytopathogenicity of the alphavirus replicase (Lundstrom, K., *Curr. Opin. Biotechnol.* 8:578-582 (1997)).

[0012] Among the features which make Alphavirus vectors attractive as transient expression systems are the easy construction of plasmid clones, a rapid gene expression (within 24h), a high level of expression, a wide host range of the virus (many insect, avian and mammalian cells), production of high-titered stocks of infectious particles and low risk of cell transformation due to the RNA nature of the genome and its replication entirely in the host cell cytoplasm without going through DNA intermediates. (Schlesinger S., 2000, *Exp. Opin. Biol. Ther.*, 1, 2, 177-191; Schlesinger S., *Adv. Virus res.*, v55, 565-577; Garoff, H. and K.J. Li, 1998, *Curr. Opin. Biotechnol.*, 9, 464-469; Lundstrom, K., 1997, *Curr. Opin. Biotechnol.*, 8, 578-583; Xiong et al., 1989, *Science*, 243, 1188-1191). Blasey et al. compared the Semliki Forest Virus (SFV) expression system with the Epstein-Barr Virus (EBV) system (pCEP4 and HEK293EBNA cells) for expression of 5-HT3 receptors and found that both systems allow the production of functional recombinant protein within days to weeks at very high comparable levels (in: *Animal Cell Technology*, 1999, pp331-337).

[0013] One of the variants of alphavirus vectors is the replicon, which is capable of self-replication in the host cytoplasm after introduction into the cultured cells by transfection. In this replicon, viral structural protein genes have been replaced by a gene of interest (GOI). Such a replicon can be introduced into cells as RNA or cDNA if placed under the control of an eukaryotic promoter or a promoter, which is recognized by the host cell machinery. (Agapov et al., *Proc. Natl. Acad. Sci. USA* 95:12989-12994 (1998)).

- [0014] RNA viruses have been engineered into chimeric viruses producing heterologous proteins. Such RNA virus vectors have been developed from Alphaviruses (with positive strand genome), Influenza and VSV (with negative strand genome). One of the major advantages of these viruses is their RNA-only replication strategy performed entirely in the cell cytoplasm and eliminating the risk of genome integration.
- [0015] Adeno-, Adeno-associated and Retrovirus vectors can be used as gene therapy vectors and/or as expression vectors, especially for large-scale protein production. Herpesvirus derivative vectors containing a replication origin have been used for bioreactor protein production after transient transfection of a suitable cell line carrying a replication initiation gene. (Durocher *et al.*, *Nucleic Acids Res.* 30(2):E9 (2002); Meissner *et al.*, *Biotechnol. Bioeng.* 75(2):197-203 (2001)). In these experiments, 293E cells (293 human embryo kidney cells expressing Epstein-Barr virus nuclear antigen - EBNA-1) were used which provided a replication initiation factor in trans to a plasmid carrying EBV origin of replication - OriP. Reporter genes (encoding secreted, intracellular or transmembrane proteins) were constitutively expressed over a period of several days.
- [0016] Hybrid vectors have also been reported, mainly as gene delivery systems or for use in virus biology research, such as combinations between EBV episomes and Herpes-, Adeno- (DNA) or Retro- (RNA-DNA) viruses (Sena-Esteves M. *et al.*, 1999, *Virol. Dec*;73(12):10426-39; Tan BT. *et al.*, 1999, *J Virol. Sep*;73(9):7582-9; Grignani F. *et al.*, 1998, *Cancer Res Jan* 1;58(1):14-9; Wang S. and Vos JM., 1996, *J Virol. Dec*;70(12):8422-30). EBV episomes are nuclear plasmids that are stably maintained through multiple cell divisions in primate and canine cells (J. L. Yates, N. Warren, and B. Sugden, 1985, *Nature* 313:812-815).
- [0017] The ability to precisely control the expression of genes introduced into animal or human cells, or in whole organisms, enables significant progress in many areas of biology and medicine. For instance, methods that allow the intentional manipulation of gene expression will facilitate the analysis of genes whose expression cannot be tolerated constitutively.

- [0018] To be of broad benefit, gene regulation techniques preferably allow for rapid, robust, precise and reversible induction of gene activity. As reviewed in Saez, E. *et al.*, (*Curr. Opin. Biotechnol.* 8:608-616 (1997)), an ideal system would fulfill the following requirements:
- [0019] 1. Specificity -- The system should be indifferent to endogenous factors and activated only by exogenous stimuli.
- [0020] 2. Non-interference -- The components of the system should not affect unintended cellular pathways.
- [0021] 3. Inducibility -- In the inactive state, the basal activity of the system should be minimal, while in the active state high levels of gene expression should be rapidly inducible.
- [0022] 4. Bioavailability of the inducer -- Inducing stimuli should rapidly penetrate to the site of interest.
- [0023] 5. Reversibility -- Inducing stimuli should clear swiftly to allow the system to rapidly return to the inactive state.
- [0024] One common system currently in use for the regulation of gene expression is the tetracycline-based system (Gossen and Bujard, *Proc. Natl. Acad. Sci. USA* 89:5547 (1992)). This system is based on the continuous expression of a fusion protein with the tetracycline repressor protein (tetR) being converted into an activator by fusion to the transcriptional activation domain of the VP16 protein. The tTA system is useful for, *e.g.*, inducible gene expression and has been successfully used for the production of a number of proteins (Wimmel *et al.*, *Oncogene* 9:995 (1994); Fröh *et al.*, *EMBO J.* 13:3236 (1994); Yu *et al.*, *J. Virol.* 70:4530 (1996)). However, there are certain disadvantages associated with the tTA system. (Schocket *et al.*, *Proc. Natl. Acad. Sci. USA* 92:6522 (1995); Howe *et al.*, *J. Biol. Chem.* 23:14168 (1995); Schocket and Schatz, *Proc. Natl. Acad. Sci. USA* 93:5173 (1996); Bohl *et al.*, *Nat. Med.* 3:299 (1997); Furth *et al.*, *Proc. Natl. Acad. Sci. USA* 91:9302 (1994); Hennighausen *et al.*, *J. Cell. Biochem.* 59:463 (1995); Kistner *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10933 (1996); Hoffmann *et al.*, *Nucleic Acids Res.* 25:1078 (1997)).

- [0025] Inducible expression systems based on viral expression vectors (*e.g.*, alphaviral vectors) are described in WO 99/50432 (incorporated herein by reference in its entirety). An exemplary alphaviral vector is pCytTs (also known as CytTs; *cf.* WO 99/50432). Using these systems, it is possible to precisely induce and regulate gene expression. This precise regulation results from the use of a temperature-sensitive RNA-dependent RNA polymerase (*i.e.*, a replicase), which only replicates RNA molecules, to form new RNA molecules, at permissive temperatures (Boorsma et al. *Nature Biotech.* 18:429-432 (2001)). Due to the extremely tight regulation of these systems it is possible to obtain regulated gene expression even under conditions of transient transfection allowing the production of toxic proteins under these conditions.
- [0026] Another example of an alphaviral expression vector is described in Lundstrom *et al.*, *FEBS Lett* 504:99-103 (2001). Lundstrom describe a rapidly generated high-titer Semliki Forest virus (SFV) vectors capable of infecting numerous mammalian cell lines and primary cell cultures, resulting in high levels of transgene expression. SFV-based expression of transmembrane receptors has been characterized by specific ligand-binding activity and functional responses. Adaptation of the SFV technology for mammalian suspension cultures has allowed the production of hundreds of milligrams of recombinant receptor for purification and structural studies. The same SFV stock solutions used for the infection of mammalian cells in culture have also been successfully applied for efficient transgene expression in organotypic hippocampal slices, as well as in vivo in rodent brain.
- [0027] A need exists in the art, however, for compositions and methods that allow the production of polypeptides and untranslated RNA molecules.

BRIEF SUMMARY OF THE INVENTION

- [0028] The present invention provides compositions and methods that allow the production of polypeptides and/or untranslated RNA molecules. More specifically, the invention provides nucleic acid molecules, expression systems, recombinant host cells that permit the production of polypeptides

and/or untranslated RNA molecules. Also provided are methods for making the nucleic acid molecules, expression systems and host cells of the invention. The invention further provides methods for producing polypeptides and/or untranslated RNA molecules. The invention also provides kits that comprise the nucleic acid molecules, expression systems and/or recombinant host cells of the invention.

[0029] In certain embodiments, the invention provides compositions and methods for regulated, expression of polypeptides or untranslated RNA molecules in recombinant host cells, preferably by way of transfection. The present invention also provides nucleic acid molecules and methods which allow, *e.g.*, rapid and high level production of specific RNA molecules produced in, *e.g.*, transiently transfected, recombinant host cells.

[0030] According to certain aspects of the invention, novel, preferably inducible, potent and rapid expression systems are provided comprising one or more nucleic acid molecules. The nucleic acid molecules of the expression systems of the invention may be maintained at, or accumulated to, multiple copies in the nuclei of recombinant host cells, preferably of transiently transfected mammalian cells. In certain embodiments, RNA self replication may lead to the accumulation of a high number of RNA molecules in the cytoplasm of the transfected cells and subsequent translation of the polypeptide of interest. The nucleic acid molecules and expression systems of the invention are particularly useful for transient transfection.

[0031] The present invention further provides nucleic acid molecules and methods which allow inducible rapid and high level production of specific RNA molecules produced in, preferably transiently transfected, recombinant host cells. In certain embodiments, RNA self-replication is preferably inducible and triggered by a temperature shift. Thus, the high production levels, in certain embodiments, are achieved by the use of a temperature-sensitive RNA-dependent RNA polymerase (*i.e.*, a replicase) which only replicates RNA molecules to form new RNA molecules at permissive temperatures. Moreover, if desired, the amount of RNA or polypeptide can be tightly regulated by the use of a temperature-sensitive RNA-dependent RNA

polymerase. This facilitates, in particular, production of growth-inhibitory or toxic polypeptides or RNA-species.

[0032] In a general aspect, the present invention provides for a nucleic acid molecule comprising (A) a first polynucleotide element which encodes an RNA molecule, said RNA molecule comprising (a) at least one *cis*-acting sequence element; (b) a first nucleotide sequence comprising a first open reading frame, said first open reading frame having a nucleotide sequence encoding an RNA-dependent RNA polymerase; and (c) at least one second nucleotide sequence selected from the group consisting of (i) a second open reading frame encoding a polypeptide; (ii) a nucleotide sequence complementary to all or part of the second open reading frame of (i); and (iii) a nucleotide sequence encoding an untranslated RNA molecule or complement thereof; wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said RNA-dependent RNA polymerase; (B) a second DNA element comprising an origin of replication; and (C) a third DNA element encoding a replication initiation factor capable of recognizing the origin of replication. Thus, the replication initiation factor preferably recognizes the origin of replication leading to replication of the second polynucleotide and second DNA element, respectively, comprising the origin of replication.

[0033] In certain embodiments, the RNA-dependent RNA polymerase is, *e.g.*, a non-cytopathic RNA-dependent RNA polymerase. In other embodiments, the RNA-dependent RNA polymerase is, *e.g.*, a temperature-sensitive RNA-dependent RNA polymerase. In yet other embodiments, the RNA-dependent RNA polymerase is, *e.g.*, a non-cytopathic, temperature-sensitive RNA-dependent RNA polymerase.

[0034] The nucleic acid molecules of the invention, in certain embodiments, comprise a 5' promoter which is capable of initiating transcription *in vivo*, 5' and/or 3' sequences enabling replication of the RNA molecule (*cis*-acting sequence elements), and a subgenomic promoter 5' to the gene of interest, as well as a sequence of interest which is translatable only after one or more RNA-dependent RNA replication events. These RNA-dependent RNA

replication events are catalyzed by a, preferably regulatable, RNA-dependent RNA polymerase which may be encoded by the same mRNA molecule that is produced by transcription of the DNA vector or by a different mRNA molecule.

[0035] The inventive nucleic acid molecules, expression systems and vector systems of the present invention thus allow for large-scale transient transfection and very rapid production of polypeptides eliminating the need of isolating stably transformed high producing cell clones. The preferred embodiment and hereby the inducibility of the vector makes the invention especially suitable for the production of cytotoxic polypeptides, *e.g.*, polypeptides that are detrimental to the viability of a host cell.

[0036] In a preferred embodiment of the present invention, the origin of replication and the replication initiation factor are derived from a DNA virus. For example, the origin of replication may be derived from a herpes virus and the replication initiation factor may be the Epstein-Barr virus nuclear antigen 1 (EBNA1). However, replication initiation factors may also derive from other viruses or be cellular factors, which are capable of recognizing or recognize viral origins of replication. As indicated, in a further embodiment, the RNA-dependent RNA-polymerase is temperature-sensitive and temperature-regulated, respectively. Preferably, the RNA-dependent RNA-polymerase is of viral, more preferably of alphaviral origin.

[0037] Thus, in a preferred embodiment, the present invention provides a hybrid vector and vector system combining the advantages of EBV episomal replication with the advantages of RNA virus replication, wherein the replication takes place entirely in the cytoplasm. This type of hybrid vector would be characterized by the maintenance of multiple copies of DNA due to polynucleotide replication, typically plasmid replication, followed by the accumulation of full-length transcripts containing the viral replicon. These viral full-length transcripts are then further exponentially amplified in the cytoplasm by the viral replicase leading to the accumulation of RNA virus replicons and protein synthesis. The system is extremely valuable for

production of toxic polypeptides if the RNA virus replication is controllable or inducible.

[0038] In a specific embodiment, the invention includes the combination of a Herpesvirus mini-replicon unit, i.e. the cis-acting replication origin OriP (Origin of replication P) and the cis- or trans-acting gene product – EBNA-1 (Epstein-Barr virus nuclear antigen 1, a replication triggering factor) with the tightly regulated temperature inducible alphaviral expression system pCytTS, as disclosed in WO 99/504332. Due to the presence of OriP and EBNA-1 the introduced novel vector is maintained episomally (extrachromosomally) in the form of several DNA copies in the cell nuclei. These multiple DNA copies may be transcribed from a promoter, typically a CMV or RSV promoter, into CytTS RNA-replicons, but they remain inactive unless cells are being shifted to a certain temperature. Only after temperature induction replicon replication takes place, followed by RNA accumulation and translation in the cell cytoplasm and production of the polypeptide of interest.

[0039] In a further general aspect, the present invention provides a vector system comprising one or more nucleic acid molecules, wherein said one or more nucleic acid molecules comprise (A) a first polynucleotide which encodes an RNA molecule, said RNA molecule comprising (a) at least one *cis*-acting sequence element; (b) a first nucleotide sequence comprising a first open reading frame having a nucleotide sequence encoding an RNA-dependent RNA polymerase; and (c) at least one second nucleotide sequence selected from the group consisting of (i) a second open reading frame encoding a polypeptide; (ii) a sequence complementary to all or part of the second open reading frame of (i); and (iii) a sequence encoding an untranslated RNA molecule, or complement thereof; wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said non-cytopathic RNA-dependent RNA polymerase; (B) a second polynucleotide comprising an origin of replication; and (C) a third polynucleotide encoding a replication initiation factor capable of recognizing the origin of replication. Thus, the replication initiation factor recognizes the

origin of replication leading to replication of the second polynucleotide and second DNA element, respectively, comprising the origin of replication.

[0040] The invention further provides single- and multiple-vector systems for producing a polypeptide or untranslated RNA molecule. In a single-vector system, the first, second and third polynucleotide are present on the same nucleic acid molecule. In a multiple-vector system, the first, second and third polynucleotide elements are present on one or more separate nucleic acid molecules. In such a multiple vector system, at least one, preferably some or more preferably all vectors contain an origin of replication. Therefore, in preferred embodiments of the invention, the replication initiation factor and the origin of replication recognizing the replication initiation factor may be on the same nucleic acid molecule and plasmid, respectively, as it is the RNA-replicase or on a separate nucleic acid molecule and plasmid, respectively.

[0041] When sequences encoding the first and second open reading frame are present either on the same nucleic acid molecule or in the same vector (i.e., in a single-vector system), a region will preferably be present 5' to the second open reading frame which inhibits translation of this open reading frame.

[0042] If a temperature sensitive RNA-dependent RNA polymerase (*e.g.*, a temperature-sensitive replicase) is included within the compositions and methods of the invention, the temperature-sensitive replicase may be "cold" or "hot" sensitive and thus will only efficiently catalyze RNA-dependent RNA replication at temperatures either above or below the restrictive temperature. In one preferred embodiment, the compositions and methods of the invention comprise, or involve the use of, an RNA-dependent RNA polymerase that has replicase activity at temperatures below 34°C which is at least five fold greater than the replicase activity exhibited at 34°C or above. Preferably, the replicase activity at temperatures below 34°C is at least ten fold greater than the replicase activity exhibited at 34°C or above. In certain embodiments, the replicase activity at temperatures below 34°C is at least one hundred fold greater than the replicase activity exhibited at 34°C or above. Temperature-sensitive RNA-dependent RNA polymerases included within the present

invention may, in certain embodiments, exhibit no (or undetectable) replicase activity at 34°C or above.

- [0043] In another aspect, the nucleic acid molecules and expression systems of the invention encode one or more cytokine, lymphokine, tumor necrosis factor, interferon, toxic protein, prodrug converting enzyme, or other polypeptide.
- [0044] In yet another aspect, the nucleic acid molecules and expression systems of the invention encode an untranslated RNA molecule, such as an antisense RNA molecule, tRNA molecule, rRNA molecule, or ribozyme.
- [0045] The invention also provides methods for making recombinant host cells comprising introducing nucleic acid molecules of the invention into host cells. Further provided are recombinant host cells produced by the introduction of nucleic acid molecules of the invention. In one embodiment, one, some or all of these recombinant host cells contain one or more nucleic acid molecules that comprise an RNA-dependent RNA polymerase and/or the replication initiation factor. The replication initiation factor, in certain embodiments, may be stably integrated into the genome of the one, some or all host cells.
- [0046] The invention further provides isolated nucleic acid molecules comprising polynucleotides which comprise the nucleotide sequence of SEQ ID NO:10 (pCytTs OriP) and SEQ ID NO:11 (pCytTs OPE).
- [0047] The present invention also provides methods for producing polypeptides and untranslated RNA molecules in recombinant host cells, said methods comprising introducing a nucleic acid molecule of the invention into a host cell to produce a recombinant host cell, and culturing the recombinant host cell under conditions suitable for expression of said polypeptide or untranslated RNA molecule. The methods of the invention may further comprise recovering said polypeptide or untranslated RNA molecule.
- [0048] Methods are also provided for the expression of heterologous polypeptides, preferably the regulated expression of heterologous

polypeptides, including cytokines, lymphokines, tumor necrosis factors, interferons, toxic polypeptides, and prodrug converting enzymes.

[0049] Further provided are polypeptides and untranslated RNA molecules produced by the methods of the invention.

[0050] The invention also provides methods for regulating the expression of a polypeptide or an untranslated RNA molecule, said method comprising introducing nucleic acid molecules of the invention into a host cell to produce a recombinant host cell and growing said recombinant host cell under suitable culture conditions. In certain embodiments, nucleic acid molecules encoding a temperature-sensitive RNA-dependent RNA-polymerase are used. When a temperature-sensitive RNA-dependent RNA-polymerase is used, the methods according to this aspect of the invention may further comprise changing the temperature of the recombinant host cell culture from either (i) a permissive temperature to a restrictive temperature, or (ii) a restrictive temperature to a permissive temperature.

[0051] In certain embodiments, the methods of the invention involve introducing the nucleic acid molecules of the invention into prokaryotic or eukaryotic host cells to produce a recombinant host cell, and then culturing said recombinant host cell under suitable culture conditions. The recombinant host cells may be cultured, *e.g.*, in a serum-free or protein-free medium.

[0052] The present invention also provides pharmaceutical compositions comprising nucleic acid molecules of the invention and a pharmaceutically acceptable carrier.

[0053] Also included within the invention are kits comprising the nucleic acid molecules of the invention. Kits of the invention may additionally or alternatively comprise one or more expression systems of the invention and one or more recombinant host cells of the invention.

BRIEF DESCRIPTION OF THE DRAWING

[0054] Fig. 1 is a schematic representation of the pCYTts vector. The pCYTts vector contains an ampicillin resistance marker for selection in bacterial cells

and a ColE1 sequence which directs high copy number bacterial amplification. The pCYTts vector was prepared as described in Example 1.

- [0055] Figs. 2A-2D show the complete cDNA sequence of pCYTts (SEQ ID NO:1).
- [0056] Fig. 3 demonstrates CytTs-EGFP-OriPd derived expression in 293-EBNA cells. Selected cell population of 293-EBNA cells, which had been transfected with CytTs-EGFP-OriPd and selected with puromycin were either kept at 37°C or shifted to 29°C for 24 hours in order to induce the Sindbis replicon. Cells were trypsinised and analyzed by flow cytometry. Untransfected and CytTs-EGFP-OriPd transfected 293-EBNA cells either cultivated at 37°C or at 29°C, as indicated above the respective panels were analyzed. GFP expression is shown on the X-axis (FL1-H) the Y-axis shows the FL4-H fluorescence.
- [0057] Fig. 4 is a FACS analysis of BHK cells transfected with CytTs-EGFP, CytTs-EGFP-OriP and CytTs-EGFP-OPE. BHK cells were transfected with CytTs EGFP, CytTs EGFP-OriP or CytTs EGFP-OPE and selected with puromycin at a concentration 5ug/ml. Two weeks after transfection cell populations were assayed for EGFP expression. Non-induced cells (37°C) and cells induced for 3 days at 29°C were trypsinized and analyzed by flow cytometry. GFP expression is shown on the X-axis (FL1-H) the Y-axis shows the FL4-H fluorescence.
- [0058] Figs. 5A-5B demonstrate IFN β expression in BHK cells transfected with CytTs-IFN β -OPE. BHK cells were transfected with CytTs-IFN β -OPE and selected with puromycin as described in the above. BHK-CytTs-IFN β -OPE cell populations were then either kept at 37°C or shifted to 29°C for induction. Samples were taken from uninduced cells and from the induced cells 3, 4, 7 and 9 days after induction and quantitated by ELISA. The interferon concentration as international units (IU)/ml at the different time points is shown in panel A. 0 corresponds to uninduced control cells. The fold induction observed is shown in panel B.

[0059] Fig. 6 shows SEAP expression in BHK cells transfected with CytTs-SEAP-OPE. BHK cells were transfected with CytTs-SEAP-OPE and selected with puromycin as described above. BHK-CytTs-SEAP-OPE cell populations were then either kept at 37°C or shifted to 29°C for induction. Samples were taken from the uninduced cells and from the induced cells 3, 4, 7 and 9 days after induction and quantitated.

[0060] Fig. 7 demonstrates the improved EPO expression from pCytTS-OPE-EPO compared to pCytTS-OriP-EPO in 293 EBNA1 cells. Selected cell populations which had been transfected either with pCytTS-OPE-EPO or with pCytTS-OriP-EPO were either kept at 37°C or shifted to 29°C in order to induce the Sindbis replicon. Samples were taken from the induced and uninduced cells 0, 4 and 8 days after induction and were quantified by ELISA. The EPO concentration at the different time points is shown in mg/l on the Y-axis.

[0061] Figs. 8A-8E show the nucleotide sequence of pCytTs OriP (SEQ ID NO:10)

[0062] Figs. 9A-9E Show the nucleotide sequence of pCytTs OPE (SEQ ID NO:11).

DETAILED DESCRIPTION OF THE INVENTION

OVERVIEW

[0063] The present invention is directed to compositions and methods that are useful, *e.g.*, in the production of polypeptides and/or untranslated RNA molecules in host cells. The compositions and methods of the invention are also useful, *e.g.*, for the isolation and/or purification of polypeptides, polypeptides and untranslated RNA molecules that are produced in host cells.

[0064] According to one aspect of the invention, nucleic acid molecules are provided. The nucleic acid molecules of the invention comprise: (A) a first polynucleotide element which encodes an RNA molecule, said RNA molecule comprising: (a) at least one *cis*-acting sequence element; (b) a first nucleotide

sequence comprising a first open reading frame, said first open reading frame having a nucleotide sequence encoding an RNA-dependent RNA polymerase; and (c) at least one second nucleotide sequence selected from the group consisting of: (i) a second open reading frame encoding a polypeptide; (ii) a nucleotide sequence complementary to all or a part of the second open reading frame of (i); and (iii) a nucleotide sequence encoding an untranslated RNA molecule or complement thereof; wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said RNA-dependent RNA polymerase; (B) a second polynucleotide element comprising an origin of replication; and (C) a third polynucleotide element encoding a replication initiation factor capable of recognizing said origin of replication.

[0065] According to another aspect of the invention, expression systems are provided. The expression systems of the invention comprise one or more nucleic acid molecules, wherein said one or more nucleic acid molecules comprise: (A) a first polynucleotide element which encodes an RNA molecule, said RNA molecule comprising: (a) at least one *cis*-acting sequence element; (b) a first nucleotide sequence comprising a first open reading frame, said first open reading frame having a nucleotide sequence encoding an RNA-dependent RNA polymerase; and (c) at least one second nucleotide sequence selected from the group consisting of: (i) a second open reading frame encoding a polypeptide; (ii) a nucleotide sequence complementary to all or a part of the open reading frame of (i); and (iii) a nucleotide sequence encoding an untranslated RNA molecule or complement thereof; wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said RNA-dependent RNA polymerase; (B) a second polynucleotide element comprising an origin of replication; and (C) a third polynucleotide element encoding a replication initiation factor capable of recognizing said origin of replication.

[0066] In the expression systems of the invention, said first, second and third polynucleotide elements may each be on a separate nucleic acid molecule. Alternatively, said first, second and third polynucleotide elements may each be on a single nucleic acid molecule. In certain embodiments, said first and

second polynucleotide elements will be on a single nucleic acid molecule while said third polynucleotide element is on a different nucleic acid molecule. In certain other embodiments, said first and third polynucleotide elements will be on a single nucleic acid molecule, while said second polynucleotide element is on a different nucleic acid molecule. In certain other embodiments, said second and third polynucleotide elements will be on a single nucleic acid molecule, while said first polynucleotide element is on a different nucleic acid molecule.

[0067] According to another aspect of the invention, recombinant host cells and *in vitro* cell cultures comprising recombinant host cells are provided. The recombinant host cells of the invention comprise: (A) a first polynucleotide element which encodes an RNA molecule, said RNA molecule comprising: (a) at least one *cis*-acting sequence element; (b) a first nucleotide sequence comprising a first open reading frame, said first open reading frame having a nucleotide sequence encoding an RNA-dependent RNA polymerase; and (c) at least one second nucleotide sequence selected from the group consisting of: (i) a second open reading frame encoding a polypeptide; (ii) a nucleotide sequence complementary to all or a part of the second open reading frame of (i); and (iii) a nucleotide sequence encoding an untranslated RNA molecule or complement thereof; wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said RNA-dependent RNA polymerase; (B) a second polynucleotide element comprising an origin of replication; and (C) a third polynucleotide element encoding a replication initiation factor capable of recognizing said origin of replication.

[0068] According to another aspect of the invention, methods are provided for producing, or regulating the expression of, a polypeptide or untranslated RNA molecule. The methods according to this aspect of the invention comprise: (a) introducing a nucleic acid molecule or an expression system of the invention into a host cell to produce a recombinant host cell; and (b) culturing said recombinant host cell. The methods of the invention may further comprise recovering said polypeptide or untranslated RNA molecule.

- [0069] According to another aspect of the invention, kits are provided comprising the nucleic acid molecules, expression systems and/or host cells of the invention.
- [0070] In certain embodiments, said second open reading frame that is included within the compositions and methods of the invention is in a translatable format after one or more RNA-dependent RNA replication events. The expression "a translatable format" is intended to mean an RNA from which a protein can be made.
- [0071] The RNA-dependent RNA polymerase that is included in, or used with, the compositions and methods of the invention may, in certain embodiments, be selected from the group consisting of: (a) a temperature-sensitive RNA-dependent RNA polymerase, (b) a non-cytopathic RNA-dependent RNA polymerase, and (c) a temperature-sensitive, non-cytopathic RNA-dependent RNA polymerase.
- [0072] When the RNA-dependent RNA polymerase that is included in, or used with, the compositions and methods of the invention is temperature sensitive, the temperature-sensitive RNA-dependent RNA polymerase may have replicase activity at temperatures below 34°C which is at least five fold, at least ten fold, at least twenty fold, at least thirty fold, at least forty fold, at least fifty fold, at least one hundred fold, or at least one thousand fold greater than the replicase activity exhibited at 34°C or above. For example, the temperature-sensitive RNA-dependent RNA polymerase may have replicase activity at 34°C that is at least five fold greater than the replicase activity exhibited at 29°C. The temperature-sensitive RNA-dependent RNA polymerase may, in certain embodiments, exhibit no or undetectable replicase activity (using methods of detection known in the art) at 34°C or above.
- [0073] The RNA-dependent RNA polymerase that is included in, or used with, the compositions and methods of the invention may, in certain embodiments, be of viral origin. For example, the RNA-dependent RNA polymerase may be of alphaviral origin. In specific embodiments of the invention, the RNA-dependent RNA polymerase is derived from a Sindbis virus, a Semliki Forest virus or an Aura virus. The RNA-dependent RNA

polymerase may be derived from a virus selected from the group consisting of Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine encephalomyelitis virus, Fort Morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus.

[0074] The origin of replication that is included in, or used with, the compositions and methods of the invention may be derived from a prokaryotic organism, a eukaryotic organism (*e.g.*, a yeast, insect or mammal), or a virus. For example, the origin of replication may be derived from a DNA virus, *e.g.*, a DNA virus that allows for episomal replication. The origin of replication may be derived from a DNA virus selected from the group consisting of Herpesvirus, Epstein-Barr virus (EBV), Papillomavirus, Polyomavirus, Adenovirus, and Hepadnavirus. In a specific embodiment, the origin of replication is *oriP*, derived from EBV.

[0075] The replication initiation factor that is included in, or used with, the compositions and methods of the invention is, in certain embodiments, capable of operating as a plasmid maintenance factor. As used herein, the term "plasmid maintenance factor" is intended to mean a factor, which supports the distribution of the episomes to the daughter cells upon cell division. In the case of EBNA-1, this is achieved by the binding of the protein to the episome and, at the same time, to the chromosome, thereby leading to proper distribution of the episomes to the daughter cells. The replication initiation factor may be derived from a prokaryotic organism, a eukaryotic organism (*e.g.*, a yeast, insect or mammal), or a virus. For example, the replication initiation factor may be derived from a DNA virus, *e.g.*, a DNA virus that allows for episomal replication. The replication initiation factor may be derived from a DNA virus selected from the group consisting of Herpesvirus, Epstein-Barr virus (EBV), Papillomavirus, Polyomavirus, Adenovirus, and Hepadnavirus. In a specific embodiment, the replication initiation factor is the EBNA-1 protein, derived from EBV.

- [0076] The origin of replication and the replication initiation factor that are included in, or used with, the compositions and methods of the invention may, in certain embodiments, be derived from the same organism or the same virus. Alternatively, the origin of replication and the replication initiation factor may be derived from different organisms or viruses.
- [0077] The nucleic acid molecules and expression systems of the invention may further comprise a fourth polynucleotide element, wherein said fourth polynucleotide element comprises a selection marker. Any selection marker known in the art may be used, including, *e.g.*, markers that confer resistance to antibiotics. An exemplary selection marker is one that confers resistance to puromycin.
- [0078] The second open reading frame that is included in, or used with, the compositions and methods of the invention may encode, in certain embodiments, any polypeptide of interest. For example, the second open reading frame may encode, *e.g.*, a cytokine, a lymphokine, a tumor necrosis factor, an interferon (*e.g.*, beta-interferon, including human beta-interferon), a toxic polypeptide, or a prodrug.
- [0079] The second open reading frame that is included in, or used with, the compositions and methods of the invention may encode, in certain embodiments, an untranslated RNA molecule. Exemplary untranslated RNA molecules include, *e.g.*, an antisense RNA molecule, a tRNA molecule, an rRNA molecule and a ribozyme. Other useful untranslated RNA molecules are known in the art.
- [0080] Thus, in certain exemplary embodiments, the invention provides compositions and methods which allow for the production of high amounts of specific RNA molecules produced in host cells upon their transient transfection with said polynucleotides. This high production results, *e.g.*, from the use of a self-replicating episomal DNA plasmid combined with an RNA-dependent RNA polymerase, which amplifies the mRNA of interest.
- [0081] Expression, using the compositions and methods of the invention, may be regulated precisely, if necessary. Such precise regulation can be achieved, *e.g.*, from the use of a temperature-sensitive RNA-dependent RNA polymerase

which only replicates RNA molecules to form additional RNA molecules at permissive temperatures.

[0082] According to the present invention, polypeptides and/or untranslated RNA molecules may be produced in transient transfection experiments due to the use of nucleic acid molecules comprising an origin of replication and DNA encoding a protein (a factor or a DNA-dependent replicase) that can recognize the origin of replication, thereby resulting in replication of the plasmid.

[0083] The expression systems of the invention, in certain embodiments, comprise alphavirus DNA vectors that can be used to create transiently transfected cell lines. Said alphavirus DNA vectors may carry genes encoding a non-cytopathic replicase and viral non-structural proteins, thereby being able to produce high amounts of polypeptide. An induction of expression is achieved when the activity of the temperature-sensitive replicase is switched on by reducing the incubation temperature of the transfected cells from 37°C to a temperature lower than 34°C. Protein expression in the host at 37°C is, preferably, below the level of detection.

DEFINITIONS

[0084] The following definitions are provided to clarify the subject matter, which the inventors consider to be the present invention.

[0085] As used herein, a nucleic acid molecule is a sequence of contiguous nucleotides (riboNTPs, dNTPs or ddNTPs, or combinations thereof) of any length which may encode a full-length polypeptide or a fragment of any length thereof, or which may be non-coding. As used herein, the terms "nucleic acid molecule," and "polynucleotide," "polynucleotide construct," and "polynucleotide element" may be used interchangeably.

[0086] As used herein, the term "alphavirus" refers to any of the RNA viruses included within the genus *Alphavirus*. Descriptions of the members of this genus are contained in Strauss and Strauss, *Microbiol. Rev.*, 58:491-562 (1994). Examples of alphaviruses are selected from the group comprising Aura virus, Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine

encephalomyelitis virus, Fort morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Sindbis virus (SIN), Semliki forest virus (SFV), Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus.

[0087] As used herein, the term "purified" used in reference to a molecule means that the concentration of the molecule being purified has been increased relative to molecules associated with it in its natural environment. Naturally associated molecules include polypeptides, nucleic acids, lipids and sugars but generally do not include water, buffers, and reagents added to maintain the integrity or to facilitate the purification of the molecule. For example, even if mRNA is diluted with an aqueous solvent during oligo dT column chromatography, mRNA molecules are purified by this chromatography if naturally associated nucleic acids and other biological molecules do not bind to the column and are separated from the subject mRNA molecules.

[0088] As used herein, the term "isolated" used in reference to a molecule means that the molecule has been removed from its native environment. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated." Further, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Isolated RNA molecules include *in vivo* or *in vitro* RNA replication products of DNA and RNA molecules. Isolated nucleic acid molecules further include synthetically produced molecules. Additionally, vector molecules contained in recombinant host cells are also isolated. Thus, not all "isolated" molecules need to be "purified."

[0089] As used herein, the phrase "low or undetectable," when used in reference to gene expression level, refers to a level of expression which is either significantly lower than that seen when the gene is maximally induced (e.g., at least five fold lower) or is not readily detectable by the methods used in the following examples section.

- [0090] As used herein, the phrase "individual" refers to multicellular organisms and includes both plants and animals. Preferred multicellular organisms are animals, more preferred are vertebrates, even more preferred are mammals, and most preferred are humans.
- [0091] As used herein, the phrase "*cis*-acting" sequence refers to nucleic acid sequences to which a replicase binds to catalyze the RNA-dependent replication of RNA molecules. These replication events result in the replication of the full-length and partial RNA molecules and, thus, the alphavirus subgenomic promoter is also a "*cis*-acting" sequence. *Cis*-acting sequences may be located at or near the 5' end, 3' end, or both ends of a nucleic acid molecule, as well as internally.
- [0092] As used herein, the phrase "RNA-dependent RNA polymerase" refers to a polymerase which catalyzes the production of an RNA molecule from another RNA molecule. This term is used herein synonymously with the term "replicase."
- [0093] As used herein, the phrase "non-infective packaged RNA molecules" refers to packaged RNA molecules which will essentially undergo only one round of host cell infection and are not pathogenic. These molecules are thus "infective" but only for a single infectious entry into a host cell and are not capable of reproducing to form additional infectious particles.
- [0094] As used herein, the term "transcription" refers to the production of RNA molecules from DNA templates catalyzed by RNA polymerases.
- [0095] As used herein, the phrase "RNA-dependent RNA replication event" refers to processes which result in the formation of an RNA molecule using an RNA molecule as a template.
- [0096] As used herein, the term "vector" refers to an a polynucleotide construct, typically a plasmid or a virus, used to transmit genetic material to a host cell. Preferably, the term "vector" as used herein refers to an agent such as a plasmid, and even more preferably to a circular plasmid. A vector as used herein may be composed of either DNA or RNA. Preferably, a vector as used herein is composed of DNA.

- [0097] As used herein, the term "heterologous sequence" refers to a second nucleotide sequence present in a vector of the invention. The term "heterologous sequence" also refers to any amino acid or RNA sequence encoded by a heterologous DNA sequence contained in a vector of the invention. Heterologous nucleotide sequences can encode polypeptides or RNA molecules normally expressed in the cell type in which they are present or molecules not normally expressed therein (*e.g.*, Sindbis structural proteins).
- [0098] As used herein, the phrase "untranslated RNA" refers to an RNA sequence or molecule which does not contain an open reading frame or encodes an open reading frame, or portion thereof, but in a format in which an amino acid sequence will not be produced (*e.g.*, no initiation codon is present). Examples of such molecules are tRNA molecules, rRNA molecules, and ribozymes. Antisense RNA may be untranslated but, in some instances antisense sequences can be converted to a translatable sense strand from which a polypeptide is produced.
- [0099] As used herein, the phrase "temperature-sensitive" refers to an enzyme which readily catalyzes a reaction at one temperature but catalyzes the same reaction slowly or not at all at another temperature. An example of a temperature-sensitive enzyme is the replicase protein encoded by the pCytT vector, which has readily detectable replicase activity at temperatures below 34°C and has low or undetectable activity at 37°C.
- [00100] As used herein, the phrase "permissive temperature" refers to temperatures at which an enzyme has relatively high levels of catalytic activity.
- [00101] As used herein, the phrase "restrictive temperature" refers to temperatures at which an enzyme has low or undetectable levels of catalytic activity. Both "hot" and "cold" sensitive mutants are known and, thus, a restrictive temperature may be higher or lower than a permissive temperature.
- [00102] As used herein, the term "recombinant host cell" refers to a host cell into which one or more nucleic acid molecules of the invention have been introduced.

[00103] As used herein, the term "replication initiation factor" refers to a protein or a DNA sequence encoding such a protein that is able to recognize an origin of replication leading to replication of plasmids containing this origin of replication.

[00104] As used herein, the term "origin of replication" refers to a DNA sequence that is recognized by a replication initiation factor or a DNA replicase leading to replication of a plasmid containing the origin of replication. The expression "recognized by a replication initiation factor" is intended to mean that a replication initiation factor can physically interact with all or a portion of an origin of replication sequence, thereby causing or stimulating molecular mechanisms that ultimately cause all or a portion of the DNA molecule comprising the origin of replication to be replicated.

[00105] As used herein the term "inducible" means that in an inactive state, the basal activity of a system should be minimal, while in the active state high levels of gene expression should be rapidly inducible.

[00106] When the terms "one," "a," or "an" are used in this disclosure, they mean "at least one" or "one or more," unless otherwise indicated.

NUCLEIC ACID MOLECULES AND EXPRESSION SYSTEMS

[00107] Certain preferred embodiments of the present invention are based on the vectors used in the previously described pCytTs expression system (WO 99/50432, the disclosure of which is hereby incorporated by reference in its entirety). These vectors are constitutively transcribed in host cells to produce mRNA molecules having two open reading frames. These open reading frames, which may or may not be produced from the same nucleic acid molecule, encode a temperature-sensitive replicase and a heterologous gene of interest. The first open reading frame is translated to produce an RNA-dependent RNA polymerase. The second open reading frame, encoding all or part of one or more polypeptides of interest, is not translated until after at least one RNA-dependent RNA replication event.

[00108] The nucleic acid molecule of the present invention comprise, *inter alia*, at least one second nucleotide sequence. The second nucleotide sequence is preferably operably linked a promoter which is recognized by an RNA-dependent RNA polymerase. The second nucleotide sequence, in certain embodiments, may comprise a second open reading frame, or other nucleotide sequence of interest, as well as other elements. For instance, the second nucleotide sequence may comprise a 5' promoter which is capable of initiating synthesis of RNA *in vivo*, 5' and/or 3' sequences enabling replication of the RNA molecule (5' and 3' *cis* acting sequence elements), as well as a sequence of interest which is translatable only after at least one replication event. Replication is catalyzed by an RNA-dependent RNA polymerase which is encoded alternatively on the same or on a different mRNA molecule. The sequence of interest may be encoded in sense, plus (+), orientation downstream of a viral RNA promoter. Translation of the coding sequence of the gene of interest is inhibited by a 5' sequence which, in the case of the single-vector system, will generally be the replicase sequence. In the multiple-vector system, a 5' sequence can inhibit translation by having one or more short open reading frames with associated stop codons which lead to the detachment of ribosomes. Similarly, any sequence which inhibits the traveling or binding of ribosomes to the sequence of interest can be used as a 5' sequence which inhibits translation (Voet and Voet, BIOCHEMISTRY, John Wiley & Sons, Inc. (1990)).

[00109] Another method for preventing translation of nucleotide sequences in most biological systems involves the insertion of the sequence in an antisense direction. This method of inhibiting translation is based on the principle that translation will generally only occur after the replication of this minus (-) strand RNA into a plus strand having an open reading frame in a sense orientation. The translated sense strand is formed by RNA replication and serves as a template for ribosomes and protein synthesis. As shown previously (WO 99/50432) production of amino acid sequences can occur even when the gene of interest is inserted into the DNA molecule in an orientation which will result in the formation of antisense RNA sequence 3' to

the subgenomic promoter. Thus, the second open reading frame may also comprise a sequence complementary to all or part of the second open reading frame described above and expression of the encoded amino acid sequence will still occur. When the production of an untranslated antisense RNA sequence is desired, the RNA molecule can be designed so that it will not serve as a template for protein synthesis. For example, the RNA can be designed so that an initiation codon is not present.

[00110] The second nucleotide sequence may alternatively or additionally comprise a nucleotide sequence encoding an untranslated RNA molecule or complement thereof. For example, RNA molecules directly produced by transcription of a DNA sequence of the invention may encode RNA sequences which are neither translated nor present in an antisense orientation. Examples of such untranslated RNA molecules include tRNA molecules, rRNA molecules, and ribozymes. A considerable number of ribozyme sequences with defined catalytic activities are known in the art (*see, e.g.*, Brown, J., *Nucleic Acids Res.* 26:351-352 (1998); Xie, Y. *et al.*, *Proc. Natl. Acad. Sci. USA* 94:13777-13781 (1997); Lavrovsky, Y. *et al.*, *Biochem. Mol. Med.* 62:11-22 (1997); Chapman, K. and Szostak, J., *Chem. Biol.* 2:325-333 (1995)). Further, ribozymes have been used to "knockout" the expression of a specific gene in eukaryotic cells as part of a ribozyme-mediated, message deletion strategy (Xie, Y. *et al.*, *Proc. Natl. Acad. Sci. USA* 94:13777-13781 (1997)). Additionally, alphaviral replicons have been used to express a functional ribozyme in mammalian cells (Smith S. *et al.*, *J. Virol.* 71:9713-9721 (1997)). The regulated expression of such ribozymes, and other untranslated RNA molecules, is thus within the scope of the present invention.

[00111] The nucleic acid molecules and expression systems of the invention also comprise a second polynucleotide element comprising an origin of replication. Origins of replication that can be used with the present invention include, *e.g.*, those that are derived from prokaryotic organisms, eukaryotic organisms (*e.g.*, yeasts, insects, or mammals) and/or viruses. For example, an origin of replication that may be used with the present invention is one that is derived from a DNA virus such as, *e.g.*, a Herpesvirus, a Papillomavirus, an

Adenovirus, or a Hepadnavirus. In certain embodiments, the origin of replication that is used with the invention is a DNA virus that allows for episomal replication. In a preferred embodiment, the origin of replication is derived from Epstein-Barr virus (EBV), such as, *e.g.*, *oriP*.

[00112] The nucleic acid molecules and expression systems of the invention also comprise a third polynucleotide element encoding a replication initiation factor. The replication initiation factor will be capable of recognizing the origin of replication that is included within the nucleic acid molecule or expression system. The third polynucleotide element of the invention may encode, *e.g.*, a replication initiation factor derived from prokaryotic organism, eukaryotic organism (*e.g.*, yeasts, insects, and/or mammals) and/or viruses. For example, a replication initiation factor that may be used with the present invention is one that is derived from a DNA virus such as, *e.g.*, a Herpesvirus, a Papillomavirus, an Adenovirus, or a Hepadnavirus. In certain embodiments, the replication initiation factor that is used with the invention is capable of operating as a plasmid maintenance factor. In a preferred embodiment, the replication initiation factor is derived from Epstein-Barr virus (EBV), such as, *e.g.*, the EBNA-1 protein, or a portion thereof.

[00113] The replication initiation factor (*e.g.*, a nucleotide sequence that encodes a replication initiation factor) and the origin of replication that are included within the nucleic acid molecules and expression systems of the present invention may be derived from the same organism or from the same virus. Alternatively, the replication initiation factor and the origin of replication may be derived from different organisms or from different viruses.

[00114] In an exemplary embodiment of the invention, nucleic acid molecules are provided that are constructed by introducing defined Epstein-Barr virus (EBV) sequences into vectors such as, *e.g.*, those included within the pCytTs system. The resulting exemplary nucleic acid molecules of the invention are capable of replicating as non-integrated autonomous episomal molecules in the transformed host cells.

[00115] The defined sequences, which may be introduced into the vectors of the pCytTs system, comprise, *e.g.*, either one or two elements of Epstein-Barr

virus, (OriP alone or together with EBNA-1 gene) which permit plasmid maintenance. The origin of replication OriP is a cis-acting sequence and needs to be inserted into the plasmid vector sequence. Plasmids containing this origin of replication are able to be maintained in cells expressing the replication initiation factor which recognizes the origin of replication; one of these factors is EBNA-1. EBNA-1 gene function can be provided in cis by introducing the sequence into the same plasmid or can be provided in trans by co-transfection with a second replicating or non-replicating plasmid as well as by providing it from stably transduced cell lines expressing EBNA-1 gene from an integrated copy. Furthermore, in certain embodiments, more than one copy of the sequence expressing the replication initiation factor, *e.g.* EBNA-1, is provided. For example, EBNA-1 gene function may be provided on one or more plasmids, wherein none, some or all of those plasmids may additionally comprise the origin of replication, and which plasmids are used for transfecting cell lines, preferably cell lines that have the sequence of EBNA-1 stably integrated within its genome. The presence of both OriP and EBNA1 sequences in the same plasmid renders replication less dependent on the host cell type. (Reisman, D. *et al.*, *Mol. Cell Biol.* 5: 1822-1832 (1985); Yates, J.L. *et al.*, *Nature* 313:812-815 (1985); U.S. Patent No. 4,686,186). U.S. Patent No. 4,686,186 describes the transfection of cells with a single plasmid containing the EBV OriP, the EBNA-1 gene and a gene encoding a protein of interest.

[00116] Although such cell lines have the advantage of stable long-term expression of the replication initiation factor and durable support of replication and maintenance of OriP containing plasmids, there are not many EBNA-1 expressing cell lines commercially available (ATCC : 293HEK-EBNA1 and CV1-EBNA1). Alternatively, plasmids that already carry the EBNA-1 gene and the gene of interest in cis on the same episome are used to transfect cells and commercial vectors such as pCEP4 (Invitrogen) are available. However, current vectors designed for constitutive expression of polypeptides carrying OriP and EBNA-1 on the episomal construct in cis and wherein the expression

is neither regulatable or inducible, are not applicable in cases where cell-toxic polypeptides need to be expressed.

[00117] To our knowledge, an inducible expression system having the features of a self-replicating DNA episome and that allows the expression of a polypeptide or untranslated RNA sequence of interest from a self-replicating RNA molecule, triggered by a simple temperature shift, has not been described.

[00118] Certain embodiments of the invention are directed to nucleic acid molecules which are transcribed to produce a mRNA molecule having two open reading frames, *e.g.*, one open reading frame which encodes a replicase, and another open reading frame which encodes a nucleotide sequence of interest. The nucleic acid molecules of the invention may contain a promoter sequence which drives transcription to produce mRNA molecules having coding sequences of both open reading frames. The mRNA sequences of the first open reading frame are preferably translated to produce a replicase required for the expression of the RNA sequences of the second open reading frame. The second open reading frame preferably encodes one or more polypeptides of interest. In addition, the vectors contain an origin of replication and a DNA polymerase recognizing the origin of replication.

[00119] Further, once the first mRNA molecule has been transcribed from the DNA vector, additional RNA-dependent RNA replication events may occur to amplify the first mRNA sequence and to produce RNA molecules with strand polarity which is the opposite of the first mRNA sequence.

[00120] The second open reading frame of the nucleic acid molecules of the invention will preferably only be expressed after partial replication of a full-length RNA molecule. This partial replication of the full-length RNA molecules is driven by a promoter sequence composed of RNA (*e.g.*, an alphaviral subgenomic promoter sequence). In addition, the plasmid encoding the replicase and the gene of interest will preferably replicate during division of the host cell due to the presence of origin of replication and a protein factor recognizing the origin of replication.

[00121] While the gene of interest may be encoded by the same RNA molecule as the RNA-dependent RNA replicase protein, this gene may also be encoded by a separate RNA molecule. Thus, the invention further provides both single- and multiple-vectors systems for expressing a gene of interest. Moreover, while all plasmids used preferably contain an origin of replication, the gene encoding the replication initiation factor may be on a separate plasmid or stably integrated into the genome of the host cell.

[00122] In a single-vector system of the invention, sequences encoding the first open reading frame, the second nucleotide sequence are components of the same nucleic acid molecule, the origin of replication and the initiation factor. Thus, all of the components required for regulated expression of the gene of interest and plasmid amplification are contained in a single nucleic acid molecule (*i.e.*, DNA or RNA).

[00123] In a multiple-vector system of the invention, sequences encoding the first open reading frame, or sub-portions thereof, and the second nucleotide sequence are components of different nucleic acid molecules. These multiple-vector systems thus may comprise two or more nucleic acid molecules. For example, the replicase and the gene of interest can each be encoded by different nucleic acid molecules. However, all vectors may contain an origin of replication.

[00124] While any functional promoter can be used to drive the transcription of mRNA from the nucleic acid molecule of the invention, the promoter is preferably a constitutive RNA polymerase II promoter (*e.g.*, Rous Sarcoma Virus (RSV), cytomegalovirus (CMV), simian virus 40 (SV40), myeloproliferative sarcoma virus (MPSV), glucocorticoid, metallothionein, *Herpes simplex* virus thymidine kinase (HSVTK), human immune deficiency (HIV), mouse mammary tumor virus (MMTV), human polyomavirus BK (BKV), or Moloney murine leukemia virus (MuLV) promoter). Additional promoters suitable for use in the practice of the present invention are known in the art (*see, e.g.*, Lee, A. *et al.*, *Mol. Cells* 7:495-501 (1997)).

[00125] The nucleic acid molecules of the invention may further comprise a fourth polynucleotide element, wherein said fourth polynucleotide element

comprises a selection marker. The selection marker may facilitate the cloning and amplification of the vector sequences in prokaryotic and eukaryotic organisms. In certain embodiments, the selection marker will confer resistance to a compound or class of compounds, such as an antibiotic. An exemplary selection marker that can be used with the nucleic acid molecules and expression systems of the present invention is one that confers resistance to puromycin.

[00126] The pCytTs vector contains an ampicillin resistance marker for positive selection in bacterial host cells and an *E. coli* origin of replication (*i.e.*, ColE1). A considerable number of sequences encoding additional selection markers and origins of replication are known in the art (*see, e.g.*, Sambrook, J. *et al.*, eds., MOLECULAR CLONING, A LABORATORY MANUAL, 2nd. edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Ausubel, F. *et al.*, eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John H. Wiley & Sons, Inc. (1997)).

[00127] The nucleic acid molecules and expression systems of the invention comprise a first nucleotide sequence comprising a first open reading frame, said first open reading frame having a nucleotide sequence encoding a replicase, *e.g.*, an RNA-dependent RNA polymerase. The first nucleotide sequence may, in certain embodiments, also comprise 5' and 3' *cis*-acting sequences, and junction sequences containing a subgenomic promoter.

[00128] The RNA-dependent RNA polymerases that can be used with the present invention may be of viral origin. The RNA-dependent RNA polymerase may be derived, *e.g.*, from virus selected from the group consisting of: Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine encephalomyelitis virus, Fort morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus. In a preferred embodiment, the RNA-dependent RNA polymerase of the invention is derived from an alphavirus such as, *e.g.*, a Sindbis virus, a Semliki Forest virus, and/or an Aura virus.

- [00129] In certain embodiments of the invention, the RNA-dependent RNA polymerase that is encoded by the first open reading frame of the nucleic acid molecules of the invention will be a non-cytopathic RNA-dependent RNA polymerase. The RNA-dependent RNA polymerase may, alternatively, be a temperature sensitive RNA-dependent RNA polymerase. In other embodiments, the RNA-dependent RNA polymerase may be a non-cytopathic, temperature-sensitive RNA-dependent RNA polymerase.
- [00130] When the RNA-dependent RNA polymerase that is encoded by the first open reading frame of the nucleic acid molecules of the invention is a temperature-sensitive RNA-dependent RNA polymerase, the RNA-dependent RNA polymerase may, *e.g.*, have replicase activity at temperatures below 34°C and low or undetectable replicase activity at 34°C or above. In certain embodiments, the temperature sensitive RNA-dependent RNA polymerase will be one that has replicase activity at 34°C which is at least five fold lower than the replicase activity exhibited at 29°C.
- [00131] Preferred mutations which confer a non-cytopathic phenotype are those that are in the *nsp2* gene (*e.g.*, the proline residue at position 726 is replaced with a serine or a leucine residue). Mutations are known in the art which render the replicase protein non-cytopathic (Weiss *et al.*, *J. Virol.* 33:463-474 (1980); Dryga *et al.*, *Virology* 228:74-83 (1997); Agapov *et al.*, *PNAS* 95:12989-12994 (1998)). In addition, mutations may be introduced into the nuclear localization signal of an alphaviral replicase which diminish toxicity of the replicon by, *e.g.*, modifying the distribution of the replicase-encoding sequence between the cytoplasm and the nucleus. (Rikkonen *et al.*, *Virology* 218:352-361 (1996)).
- [00132] Mutations which render a replicase non-cytopathic may be introduced by a number of means, including site directed mutagenesis. Additional mutations that render an RNA-dependent RNA polymerase non-cytopathic can be identified by, *e.g.*, random mutagenesis and screening using methods and techniques that are well-known in the art. As will be understood by persons having ordinary skill in the art, the identification of additional mutations that render an RNA-dependent RNA polymerase non-cytopathic, temperature

sensitive, or both, does not require an ability to predict the structural or functional consequences of any particular mutation.

[00133] About 20 years ago Weiss *et al.* (Weiss, B. *et al.*, *J. Virol.* 33:463-474 (1980)) established a persistently infected culture of BHK cells. The mutation responsible for this phenotype has been recently identified (Dryga, S.A. *et al.*, *Virology* 228:74-83 (1997)). Another mutation allowing the regulation of the mRNA transcription via temperature shifts was identified by Burge and Pfefferkorn (Burge, B.W. & Pfefferkorn, E.R., *Virology* 30:203-214 (1966)) and described in more detail by Xiong *et al.* (Xiong, C. *et al.*, *Science* 243:1188-1191 (1989)).

[00134] Temperature sensitivity (*ts*) may be conferred, for example, by the introduction of a mutation in the *nsp4* gene of the replicase. Preferably, mutations which confer a temperature-sensitive phenotype upon replicase activities are in a protein in complementation group F (Lemm *et al.*, *J. Virol.* 64:3001-3011 (1990)). For example, a temperature-sensitive phenotype may be conferred by changing Gly 153 of *nsp4* to Glu. Additionally, any other mutation which renders replicase activity temperature-sensitive can be used in the practice of the invention. Methods for creating and identifying new temperature-sensitive mutants are described by Pfefferkorn (Burge and Pfefferkorn, *Virol.* 30:204-213(1966); Burge and Pfefferkorn, *Virol.* 30:214-223 (1966)). Other methods will be appreciated by those of ordinary skill in the art.

[00135] While most temperature-sensitive mutants are "hot" sensitive, "cold" sensitive mutations are also known (*see, e.g.*, Schwer, B. *et al.*, *Nucleic Acids Res.* 26:803-809 (1998), Mathe, E. *et al.*, *J. Cell Sci.* 111:887-896 (1998), Doedens, J. *et al.*, *J. Virol.* 71:9054-9064 (1997), Patterson, B. *et al.*, *J. Biol. Chem.* 272:27612-27617 (1997)). The temperature-sensitive replicase may be "cold" or "hot" sensitive and thus will catalyze RNA replication only at temperatures either above or below restrictive temperatures. In one embodiment, RNA replication occurs at detectable levels only at temperatures lower than 34°C. In contrast to all previously known regulatable DNA expression systems, the basal level of expression in recombinant host cells

containing the pCytTs vector in the inactive state at 37°C is below the level of detection using standard methods (*e.g.*, those used in the following examples) even under condition of transient transfection. This low level of expression is apparent from the data presented in Fig.4.

[00136] The production of additional temperature sensitive and/or non-cytopathic replicases has been described in the art. (Lundstrom *et al.*, *Gene Ther. Mol. Biol.* 4:23-31 (1999), Lundstrom *et al.*, *Histochem. Cell. Biol.* 115:83-91 (2001)). Moreover, with respect to alphaviruses, the results obtained in one type of alphavirus can often be used to predict the results obtained in other alphaviruses. That is, the identification of mutations that render a replicase temperature-sensitive and/or non-cytopathic in one alphavirus type may be used to identify or create a similar temperature-sensitive and/or non-cytopathic replicase in a different alphavirus. This ability is related, in part, to the high level of sequence identity observed among alphavirus genomes, especially in their replicase-encoding sequences. (Weaver *et al.*, *J. Virol* 71:613-623 (1997), Smyth *et al.*, *J. Virol.* 71:818-823 (1997), Kuhn *et al.*, *J. Virol.* 70:7900-7909 (1996)).

[00137] In certain embodiments, the first nucleotide sequence (comprising a first open reading frame encoding an RNA-dependent RNA polymerase) and the second nucleotide sequence (comprising, *e.g.*, a second open reading frame encoding a polypeptide) are contained on two separate nucleic acid molecules. In such an instance, the second nucleotide sequence may carry both *cis*-acting sequences and a 5' region which inhibits translation of the sequence of interest. The first nucleotide sequence can also be encoded by a nucleic acid molecule which is different than the second nucleotide sequence. Replication and translation of the second nucleotide sequence in this multi-vectors system can be regulatable by temperature if a temperature sensitive RNA-dependent RNA polymerase is used.

[00138] Additional mutations that render an RNA-dependent RNA polymerase non-cytopathic, temperature-sensitive, or both, can be identified by, *e.g.*, random mutagenesis and screening using methods and techniques that are well-known in the art. As will be understood by persons having ordinary skill

in the art, the identification of additional mutations that render an RNA-dependent RNA polymerase non-cytopathic, temperature sensitive, or both, does not require an ability to predict the structural or functional consequences of any particular mutation. The identification of an RNA-dependent RNA polymerase that is non-cytopathic, temperature-sensitive, or both, only involves, *e.g.*, the generation of random mutations and the functional testing of the replicases that are encoded from the mutated nucleic acid molecules. Such screening methods are routine in the art.

[00139] The nucleic acid molecules and expression systems of the invention can be also used to express of more than one gene of interest. For example, recombinant host cells can be transfected with more than one nucleic acid molecule of the invention wherein one nucleic acid molecule encodes both the replicase and a polypeptide of interest and additional nucleic acid molecules may encode additional polypeptides of interest. Similarly, when mutations conferring non-cytopathicity and temperature sensitivity are both used, genes encoding polypeptides having suitable mutations (*e.g.*, Pro 726 Ser in nsp2 and Gly 153 Glu in nsp4) may be on separate nucleic acid molecules. Additional variations would be apparent to those skilled in the art.

[00140] The nucleic acid molecules of the invention may also contain packaging signals which direct the packaging of RNA molecules into viral particles. These RNA molecules can be packaged in the presence of wild-type virus or defective helper virus RNA. A significant improvement was made with the development of defective helper RNA molecules (Bredenbeek, P. *et al.*, *J. Virol.* 67:6439-6446 (1993)). These RNA molecules contain *cis*-acting sequences, required for replication of the full-length transcription product, and subgenomic RNA promoter sequences which drive the expression of the structural protein genes. For example, in cells containing both RNA molecules with packaging signals and the defective helper virus RNA, alphaviral non-structural proteins allow for replication and amplification of the defective helper virus RNA sequences which are translated to produce virion structural proteins. Since the helper virus RNA lacks packaging signals, these molecules are not packaged into assembled virions. Thus, virion particles

produced in this way contain essentially only RNA sequences encoding the gene of interest and, generally, other sequences required for temperature-sensitive regulation of gene expression. These non-infective packaged RNA molecules do not contain sequences encoding virion structural proteins and, thus, undergo only one round of host cell infection and are not pathogenic.

[00141] Non-infective packaged RNA molecules can be used to infect a culture of suitable host cells simply by adding the particles to culture medium containing these cells. The preparation of non-infective alphaviral particles is described in a number of sources, including "Sindbis Expression System", Version C, (Invitrogen Catalog No. K750-1).

[00142] One exemplary application of this system is directed to the temperature-dependent production of non-infective, packaged RNA molecules. These packaged RNA molecules may be produced by a number of means including using recombinant host cells containing two different nucleic acid molecules (*e.g.*, a nucleic acid molecule of the invention and a nucleic acid molecule encoding a helper virus RNA sequence). For example, one of these nucleic acid molecules will encode, *e.g.*, an RNA molecule which contains packaging signal sequences, sequences encoding a non-cytopathic, temperature-sensitive replicase, and the gene of interest. The other nucleic acid molecule will contain sequences encoding alphaviral structural proteins downstream from an alphavirus subgenomic promoter. Using such a system, viral particles containing only RNA molecules with packaging signals will be produced at permissive temperatures in recombinant host cells. This is so because alphaviral structural proteins will only be produced at a permissive temperature. Additional variations of the above would be apparent to one skilled in the art.

[00143] The second nucleotide sequence that is included within the nucleic acid molecules and expression systems of the invention may be, *e.g.*, a second open reading frame encoding a polypeptide. Such a second open reading frame may, alternatively or interchangeably, be referred to as a nucleotide sequence of interest. A wide variety of nucleotide sequences of interest can be expressed

by the nucleic acid molecules and expression systems of the invention. These sequences include, but are not limited to, sequences encoding lymphokines, cytokines, toxins, enzymes, prodrug converting enzymes, antigens which stimulate immune responses, single chain antibodies, polypeptides which stimulate or inhibit immune responses, tumor necrosis factors, and various proteins with therapeutic applications (*e.g.*, growth hormones and regulatory factors).

[00144] In certain embodiments, the second open reading frame (the second nucleotide sequence) of the invention may encode, *e.g.*, a cytokine or lymphokine (*e.g.*, β -interferon). Hematopoiesis is regulated by lymphokines and cytokines which stimulate the proliferation and/or differentiation of various hemopoietic cells. Representative examples of cytokines and lymphokines include interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-12 (IL-12), interleukin-13 (IL-13), interleukin-14 (IL-14), interleukin-15 (IL-15), interleukin-16 (IL-16), interleukin-17 (IL-17), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), and interferons.

[00145] In certain embodiments, the second open reading frame (the second nucleotide sequence) of the invention may encode secreted enzymes (*e.g.*, secreted alkaline phosphatase), cytoplasmic enzymes (*e.g.*, green fluorescent protein), or any number of other proteins with therapeutic applications (*e.g.*, human insulin, human coagulation Factor VIII).

[00146] The nucleic acid molecules and expression systems of the invention can also be used to express heterologous sequence encoding cytotoxic polypeptides. Cytotoxic polypeptides act to directly or indirectly inhibit cellular growth or metabolism. Representative examples of toxins include *Shigella* toxin, ricin, *Diphtheria* toxin, *Cholera* toxin, *Pseudomonas* exotoxin A, and *Herpes simplex* virus thymidine kinase (HSVTK). Within

other embodiments of this invention, the heterologous sequence encodes a prodrug converting enzyme. A prodrug converting enzyme activates a compound with little or no cytotoxicity into a toxic product. Representative examples are HSVTK, alkaline phosphatase, guanine phosphoribosyl transferase, and penicillin-V amidase. Examples of both cytotoxic polypeptides and prodrug converting enzymes are discussed in numerous sources including PCT/US97/06010, EP 0716148, and WO 96/17072. In addition, a vast array of signaling molecules and membrane proteins are toxic if expressed at high levels. All these molecules may be suitable for expression using the system of the present invention.

[00147] The second nucleotide sequence of the nucleic acid molecules and expression systems of the invention may also be a nucleotide sequence encoding an untranslated RNA molecule or complement thereof. Exemplary untranslated RNA molecules include, *e.g.*, antisense sequences, RNase P targeted sequences which induce gene down-regulation, and ribozymes. Smith S. *et al.* (*J. Virol.* 71:9713-9721 (1997)) describes alphaviral vectors used to express ribozyme sequences.

[00148] The nucleic acid molecules and expression systems of the invention can also be used to express virtually any polypeptide, including ones which have not as yet been identified but are encoded by nucleotide sequences contained in, for example, cDNA libraries or host cell chromosomes. Example of such polypeptides include secreted proteins and proteins from various cellular compartments. Heterologous sequences expressed by the vectors of the invention can encode polypeptides and RNA molecules from non-human species (*e.g.*, other mammals, plants, fungi, bacteria or viruses). These heterologous sequences may further encode viral membrane proteins (*e.g.*, HIV gp160) or viral polyproteins (*e.g.*, Sindbis structural proteins).

[00149] Nucleotide sequences may be added to the nucleic acid molecules and vectors of the invention which result in the production of a fusion protein. For example, such sequences can encode amino acids sequences which are fused to a protein encoded by a gene of interest and confer one or more functional characteristics upon the expression product. These amino acid sequences

include sequences which will target the gene product for export from the cell (e.g., a secretory sequence) or to a subcellular compartment (e.g., the nucleus). Such amino acid sequences further include sequences which facilitate purification (e.g., a six His "tag"). Depending on the amino acid sequence and the function imparted by the fused sequence, the added amino acid sequences may or may not be cleaved from the translation product.

[00150] Fusion proteins also include proteins which have domains or regions derived from various different proteins. Examples of such a fusion protein are those containing domain II of *Pseudomonas* exotoxin, a domain or amino acid sequence which has binding affinity for a cell surface receptor associated with a particular cell type, and another amino acid sequence with a preselected biological activity. Domain II of *Pseudomonas* exotoxin will translocate across cell membranes. Using this system, fusion proteins can be designed which will bind to specific cells types, will translocate across the cytoplasmic membranes of these cells, and will catalyze predetermined intracellular biological reactions. A system of this type is described in Pastan *et al.*, U.S. Patent No. 5,705,163. Methods for identifying amino acid sequences, which bind to specific cell types are described in Wu, A., *Nature Biotech.* 14:429-431 (1996).

[00151] The nucleic acid molecules and expression systems of the invention may, in certain embodiments, further comprise genetic elements which confer additional functional characteristics such as selection markers.

[00152] Markers for the selection of prokaryotic and eukaryotic cells containing vectors the present invention are well known in the art and include puromycin, tetracycline, ampicillin, neomycin, and kanamycin resistance. Nucleotide sequences which result in high copy number amplification are also known in the art and include the ColE1 sequence contained in the pCytTs vector.

RECOMBINANT HOST CELLS

[00153] The invention includes methods of making recombinant host cells and recombinant host cells produced using the methods of the invention. For example, the methods of the invention comprise introducing one or more nucleic acid molecules or expression systems described herein into a host cell. A variety of different recombinant host cells can be produced which contain the nucleic acid molecules and expression systems of the invention. Alphaviruses, for example, are known to have a wide host range. Sindbis virus, for example, infects cultured mammalian, reptilian, and amphibian cells, as well as some insect cells (Clark, H., *J. Natl. Cancer Inst.* 51:645 (1973); Leake, C., *J. Gen. Virol.* 35:335 (1977); Stollar, V. in *THE TOGAVIRUSES*, R.W. Schlesinger, Ed., Academic Press, (1980), pp.583-621).

[00154] Thus, numerous host cells can be used in the practice of the invention. Representative host cells that may be used with the invention include, but are not limited to, bacterial cells, yeast cells, plant cells and animal cells. Preferred bacterial host cells include *Escherichia* spp. cells (particularly *E. coli* cells and most particularly *E. coli* strains DH10B, Stbl2, DH5, DB3, DB3.1, DB4 and DB5), *Bacillus* spp. cells (particularly *B. subtilis* and *B. megaterium* cells), *Streptomyces* spp. cells, *Erwinia* spp. cells, *Klebsiella* spp. cells, *Serratia* spp. cells (particularly *S. marcessans* cells), *Pseudomonas* spp. cells (particularly *P. aeruginosa* cells), and *Salmonella* spp. cells (particularly *S. typhimurium* and *S. typhi* cells). Preferred animal host cells include insect cells (most particularly *Drosophila melanogaster* cells, *Spodoptera frugiperda* Sf9 and Sf21 cells and *Trichoplusia* High-Five cells), nematode cells (particularly *C. elegans* cells), avian cells, amphibian cells (particularly *Xenopus laevis* cells), reptilian cells, and mammalian cells (most particularly NIH3T3, CHO, COS, VERO, BHK, HEK, other rodent cells, and human cells). Preferred yeast host cells include *Saccharomyces cerevisiae* cells and *Pichia pastoris* cells. BHK, COS, Vero, HeLa and CHO cells are particularly suitable for the production of heterologous polypeptides because they have the potential to glycosylate heterologous proteins in a manner similar to human

cells (Watson, E. *et al.*, *Glycobiology* 4:227, (1994)) and can be selected (Zang, M. *et al.*, *Bio/Technology* 13:389 (1995)) or genetically engineered (Renner W. *et al.*, *Biotech. Bioeng.* 47:476 (1995); Lee K. *et al.* *Biotech. Bioeng.* 50:336 (1996)) to grow in serum-free medium, as well as in suspension.

[00155] Example 2 shows that the expression system of the present invention can function in BHK cells and 293HEK cells. Moreover, we have previously demonstrated that the pCytTs system works efficiently in additional cells lines such as CHO-K1 and COS-7 (Boorsma *et al.*, *Nature Biotech.* 18:429-432 (2000)).

[00156] The nucleic acid molecules and/or expression systems of the invention may be introduced into host cells using well known techniques of infection, transduction, electroporation, transfection, and transformation. Exemplary methods include DEAE-dextran mediated transfection, transient transfection, microinjection, cationic lipid-mediated transfection, scrape loading and ballistic introduction. Methods for the introduction of exogenous DNA sequences into host cells are discussed in Felgner, P. *et al.*, U.S. Patent No. 5,580,859. The nucleic acid molecules and/or vectors of the invention may be introduced alone or in conjunction with other nucleic acid molecules and/or vectors and/or proteins, peptides or RNAs. Alternatively, the nucleic acid molecules and/or expression systems of the invention may be introduced into host cells as a precipitate, such as a calcium phosphate precipitate, or in a complex with a lipid. Electroporation also may be used to introduce the nucleic acid molecules and/or expression systems of the invention into a host. Likewise, such molecules may be introduced into chemically competent cells such as *E. coli*. If the vector is a virus, it may be packaged in vitro or introduced into a packaging cell and the packaged virus may be transduced into cells. Hence, a wide variety of techniques suitable for introducing the nucleic acid molecules and/or vectors of the invention into host cells are well known and routine to those of skill in the art. Such techniques are reviewed at length, for example, in Sambrook, J., et al., *Molecular Cloning, a Laboratory Manual*, 2nd Ed., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory

Press, pp. 16.30-16.55 (1989), Ausubel, F. *et al.*, eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John H. Wiley & Sons, Inc. (1997), Chapter 16), Watson, J.D., *et al.*, Recombinant DNA, 2nd Ed., New York: W.H. Freeman and Co., pp. 213-234 (1992), and Winnacker, E.-L., From Genes to Clones, New York: VCH Publishers (1987), which are illustrative of the many laboratory manuals that detail these techniques and which are incorporated by reference herein in their entireties for their relevant disclosures.

[00157] The invention is also directed to recombinant host cells comprising one or more nucleic acid molecules or expression systems of the invention. Also included within the present invention are *in vitro* cell cultures that comprise such recombinant host cells. Methods for producing recombinant host cells and cell cultures comprising the same are well-known in the art.

PRODUCTION OF POLYPEPTIDES AND RNA MOLECULES

[00158] The nucleic acid molecules, expression systems and recombinant host cells of the invention may be used for the production of proteins, polypeptides and RNA molecules, *e.g.*, untranslated RNA molecules. The methods of the invention may comprise, *e.g.*, introducing one or more nucleic acid molecules or expression systems of the present invention into host cells to produce recombinant host cells, culturing the recombinant host cells under conditions suitable for expression of the polypeptide or untranslated RNA molecule, and recovering the polypeptide or untranslated RNA molecule.

[00159] The invention also provides methods for regulating the expression of a polypeptide or an untranslated RNA molecule. The methods of the invention may comprise, *e.g.*, (a) introducing one or more nucleic acid molecules or expression systems of the invention into a host cell to produce a recombinant host cell, wherein said nucleic acid molecules or expression systems comprise a first open reading frame having a nucleotide sequence encoding a temperature-sensitive RNA-dependent RNA polymerase, (b) growing said recombinant host cell under suitable culture conditions, and (c) changing the temperature of the recombinant host cell culture from: (i) a permissive

temperature to a restrictive temperature, or (ii) a restrictive temperature to a permissive temperature.

[00160] The present invention also provides methods for producing polypeptides and RNA molecules, said methods comprising introducing one or more nucleic acid molecules or expression systems of the invention into recombinant host cells, expanding the cells at a non-permissive temperature and incubating these cells at a permissive temperature. In a related aspect, the invention provides purified polypeptides and RNA molecules produced according to the methods of the present invention.

[00161] Depending on the molecule, which is expressed, it may be obtained either from the culture supernatant or by lysing the recombinant host cells.

[00162] Polypeptides produced using the nucleic acid molecules and expression systems of the invention can be recovered and purified from recombinant cell cultures by methods known in the art including ammonium sulfate precipitation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and high performance liquid chromatography. Methods for purifying proteins are described in numerous sources (*see, e.g.,* Celis, J., ed., CELL BIOLOGY, Academic Press, 2nd edition, (1998)).

[00163] Untranslated RNA molecules produced using the nucleic acid molecules and expression systems of the invention can be recovered and purified from recombinant cell cultures by methods known in the art (*see, e.g.,* Celis, J., ed., CELL BIOLOGY, Academic Press, 2nd edition, (1998)). Methods for recovering and/or purifying RNA molecules include phenol/chloroform extraction, digestion with DNAses followed by precipitation of the undigested RNA molecules, and column chromatography (*e.g.,* oligo dT column chromatography). Further, RNA molecules can be separated from other cellular material using the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, *Anal. Biochem.* 162:156-159 (1987).

- [00164] The overall cell culture process employing nucleic acid molecules and expression systems of the invention for the production of polypeptides and/or untranslated RNA molecules can be implemented in a variety of bioreactor configurations (e.g., stirred-tank, perfused, membrane enclosed, encapsulated cell, fluidized bed, and air-lift reactors) and scales (from laboratory T-flasks to thousands of liters), chosen to accommodate the requirements of the host cell line utilized (e.g., anchorage dependency, O₂ concentrations), to maximize the production of expression product, and to facilitate subsequent recovery and purification of expression product.
- [00165] The invention is also directed to the production of polypeptides or RNA molecules of interest using mammalian cells grown in serum-free or protein-free culture media. For example, by long-term culture under conditions restricting serum access or selecting for suspension growth, CHO cell lines are selected which are able to grow in serum-free medium and/or in suspension (Zang, M. *et al.*, *Bio/Technology* 13:389 (1995)).
- [00166] Further, a number of different bioprocess parameters can be varied in order to alter the glycosylation pattern of polypeptide products produced by the recombinant host cells of the invention. These factors include medium composition, pH, oxygen concentration, lack or presence of agitation, and, for the case of anchorage-dependent cells, the surface provided. Thus, the glycosylation pattern of glycoproteins may be altered by choosing the host cell in which these proteins are expressed in and the conditions under which the recombinant host cells are grown.

PHARMACEUTICAL COMPOSITIONS

- [00167] The invention further provides pharmaceutical compositions comprising nucleic acid molecules and/or expression systems and/or recombinant host cells of the invention. The pharmaceutical compositions of the invention may comprise nucleic acid molecules and/or expression systems and/or recombinant host cells of the invention in combination (e.g., in solution) with a physiologically acceptable carrier and in a therapeutically

effective amount. The administration of these pharmaceutical compositions may, for example, result in expression of a polypeptide in tissues of an animal which is immunogenic and intended to function as a vaccination. Similarly, the nucleic acid molecules and/or expression systems and/or recombinant host cells of the invention may carry sequences that encode polypeptides or RNA molecules required for the treatment of an active affliction. The administration of a pharmaceutical composition of the invention will thus be intended to have a therapeutic effect in these instances.

[00168] The nucleic acid molecules and/or expression systems and/or recombinant host cells of the invention will normally be administered to an individual in a pharmacologically acceptable carrier. A composition is said to be "pharmacologically acceptable" if its administration can be tolerated by a recipient individual. Further, the composition of the invention will be administered in a "therapeutically effective amount" (e.g., an amount that produces a desired physiological effect).

[00169] As would be understood by one of ordinary skill in the art, when the nucleic acid molecules and/or expression systems and/or recombinant host cells of the invention are administered to an individual, they may be in a composition which contains salts, buffers, adjuvants, or other substances which are desirable for improving the efficacy of the composition. Examples of materials suitable for use in preparing pharmaceutical compositions are provided in numerous sources including REMINGTON'S PHARMACEUTICAL SCIENCES (Osol, A, ed., Mack Publishing Co., (1980)).

[00170] The pharmaceutical compositions of the present invention can be administered by various art known means but will normally be administered by injection, infusion or other suitable physical methods. The compositions may alternatively be administered intramuscularly, intravenously, or subcutaneously. Components of compositions for administration include sterile aqueous (e.g., physiological saline) or non-aqueous solutions and suspensions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic

esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption.

- [00171] When recombinant host cells are administered to an individual, the number of cells or nucleic acid molecules required to provide a therapeutically effective amount will vary with such factors as the individual's condition, the polypeptides or RNA molecules intended to be expressed, and the size of the individual.

KITS

- [00172] The invention also provides kits comprising the isolated nucleic acid molecules, expression systems and/or recombinant host cells of the invention. The kits of the invention may optionally comprise one or more additional components selected from the group consisting of one or more containers (*e.g.*, boxes, vials, tubes, jars ampules, etc.) one or more vectors, one or more nucleotides, one or more primers, one or more polypeptides having polymerase activity, one or more host cells (*e.g.*, host cells that may be competent for uptake of nucleic acid molecules), and one or more buffers.

- [00173] It will be readily apparent to one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein are obvious and may be made without departing from the scope of the invention or any embodiment thereof. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the invention.

EXAMPLE 1

CONSTRUCTION OF THE pCytTs VECTOR SYSTEM

[00174] Manipulations and sequencing of DNA were carried out by standard procedures. The mutations in nsP2 were introduced by PCR using the following oligonucleotides:

[00175] oligo-nsP2 1: 5'-AACATTGAAATCGATATTACAGGGG (SEQ ID NO:2),

[00176] oligo-nsP2 2: 5'-CGGGTTATGGTCGACCGGGC (SEQ ID NO:3),

[00177] oligo-nsP2 3: 5'-GTGCCCTCCCCTGAGTTTAAACAATTCAGGGC CGAACGCG (SEQ ID NO:4), and

[00178] oligo-nsP2 4: 5'-GAATTGTTTAAACTCAGGAGGCACCCTCGTGG (SEQ ID NO:5).

[00179] The single restriction sites used for first analysis and subsequent cloning (*Dra*I, *Cl*aI and *Sal*I) are underlined. PCR reactions were performed using either oligo-nsP2 1 (SEQ ID NO:2) and oligo-nsP2 3 (SEQ ID NO:4) or oligo-nsP2 2 (SEQ ID NO:3) and oligo-nsP2 4 (SEQ ID NO:5). 100 pmol of each oligo was used and 5 ng of the template DNA (pSinRep5; Xiong, C. *et al.*, *Science* 243:1188-1191 (1989)) was used in the 100 μ l reaction mixture, containing 4 units of Taq or Pwo polymerase, 0.1 mM dNTPs and 1.5 mM MgSO₄. All DNA concentrations were determined photometrically using the GeneQuant apparatus (Pharmacia Biotech Inc., 800 Centennial Ave., Piscataway, NJ. 08854). The polymerase was added directly before starting the PCR reaction (starting point was 95°C). The temperature cycles were as follows: 95°C for 2 minutes, followed by 5 cycles of 95°C (45 seconds), 58°C (30 seconds), 72°C (90 seconds) and followed by 25 cycles of 95°C (45 seconds), 68°C (30 seconds), 72°C (90 seconds).

[00180] The two PCR fragment were purified using Qia spin PCR kit (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311) and finally digested in an appropriate buffer using 20 units of *Sal*I and *Dra*I, respectively 20 units of *Cl*aI and *Dra*I. The digestion was performed for 12 hours at

37°C. The DNA fragments were gel-purified (Gene-Clean; Bio 101 Inc., 1070 Joshua Way, Vista, CA, 92083, USA) and finally ligated into *ClaI/SalI* digested and gel-purified SinRep5 vector (Xiong, C. *et al.*, *Science* 243:1188-1191 (1989). The correct sequence of the obtained vector was checked by DNA sequencing of the whole nsP2 gene.

[00181] The mutations in nsP4 were also introduced by PCR using the following oligonucleotides:

[00182] oligo-nsP4 1: 5'-GGTAGACGAGACAGTCCGCATGCCTGGATAC (SEQ ID NO:6),

[00183] oligo-nsP4 2: 5'-GTATCCAGGCGATGCGACTGTCTCGTCTACC (SEQ ID NO:7),

[00184] oligo-nsP4 3: 5'-CAGACCGGTTAACGCCATAGCG TCG (SEQ ID NO:8), and

[00185] oligo-nsP4 4: 5'-CTCTATTACTAGTATGGACAGTTGG (SEQ ID NO:9),

[00186] The singular restriction sites used for the first analysis and the final cloning step (*SphI*, *HpaI* and *SpeI*) are underlined. Two PCR reactions were carried out as described above using either oligo-nsP4 1 (SEQ ID NO:6) and oligo-nsP4 3 (SEQ ID NO:8) or oligo-nsP4 2 (SEQ ID NO:7) and oligo-nsP4 4 (SEQ ID NO:9).

[00187] Both PCR products were gel-purified and then used in assembly PCR to amplify the whole nsP4 gene. For the assembly PCR, 50 pmol of the outer primers (3 and 4) and about 10 ng of each PCR fragment was used. The reaction volume was 100 µl, containing 4 units of Taq or Pwo polymerase, 0.1 mM dNTPs and 1.5 mM MgSO₄. The PCR conditions were as followed:

[00188] 95°C for 2 minutes, followed by 5 cycles of 92°C (45 seconds), 58°C (30 seconds), 72°C (120 seconds) and followed by 25 cycles of 92°C (45 seconds), 64°C (30 seconds), 72°C (120 seconds).

[00189] The obtained PCR fragment was purified as described above and the eluate was digested with 20 units of *SpeI* and *HpaI* in an appropriate buffer. The fragment was gel-purified and ligated into gel-purified *SpeI/HpaI*

restricted SinRep5 vector. The correct sequence of the obtained vector was checked by DNA sequencing.

[00190] Overnight digestion of SinRep5-nsp4mut and SinRep5-nsp2mut with *SpeI/HpaI* and gel purification of the nsp4 fragment and sinRep-nsp2mut vector. The nsp4mut fragment was ligated into the SinRep5-nsp2mut vector. The final step was cloning the nsp gene into the 987/SinRep5 vector (Bredenbeek, P. *et al.*, *J. Virol.* 67:6439-6446 (1993)) using *ClaI* and *HpaI* as restriction endonucleases, the resulting vector was named pCytTs (Fig. 1 and Figs. 2A-2D (SEQ ID NO:1)).

EXAMPLE 2

COMBINATION OF THE TEMPERATURE SENSITIVE pCytTs SYSTEM WITH THE SELF REPLICATING EBNA SYSTEM

[00191] This system was generated in order to rapidly generate cell populations, which inducibly express a gene of interest. In this system, the tightly regulated pCytTs system is combined with the episomally replicating EBV system.

A. Construction of various pCytTs constructs containing either the EBNA origin of replication (OriP) alone or in conjunction with the replication initiation factor EBNA1.

[00192] In order to be able to subclone either the origin of replication of Epstein-Barr virus alone or together with the replication initiation factor EBNA1 we first subcloned this two cassettes into a shuttle vector from which they can easily be transferred into our pCyt TS system with or without various inserts. The Epstein-Barr virus origin of replication OriP was amplified by PCR from pCEP4 (Invitrogen) using primers PH 51 and PH 52. The forward primer (PH 51) corresponds to nucleotides 261-280 of pCep4 and the reverse primer (PH 52) to nucleotides 2221-2239 of pCep4. PCR was performed using pfx polymerase (BRL) according to manufacturer's recommendations. The

resulting PCR product (nucleotides 261-2239 of pCep4) was then cloned into pGEMTeasy vector (Invitrogen), which had previously been digested with Eco RI and treated with Klenow polymerase in order to get blunt ends. The resulting plasmid was termed pGemT-OriP. In order to get a subclonable cassette containing OriP and EBNA1 gene, pCep4 was digested with Dra III and Cla I. The resulting 4651 bp fragment was purified and blunt ends were generated by T4 DNA polymerase treatment. This fragment was then subcloned into pGEMTeasy vector (Invitrogen), which had previously been digested with Eco RI and treated with Klenow polymerase in order to get blunt ends. The resulting construct was termed pGemT-OPE. From these plasmids either the origin of replication alone (pGemT-OriP) or together with the replication initiation factor (pGemT-OPE) could be excised by Not I digestion and transferred into Not I sites of the various CytTs vectors. pCytTs-IFN β , pCytTs-EGFP, pCytTs-SEAP and ecCytTs-cEPO vectors were linearized with Not I and the Not I fragment of pGemT-OPE was introduced by ligation leading to the following constructs: pCytTs-IFN β -OPE, pCytTs-EGFP-OPE, pCytTs-SEAP-OPE and pCytTs-EPO-OPE. Similarly pCytTs-EPO-OriP and pCytTs-EGFP-OriP were generated by cloning the Not I fragment from pGemT-OriP into the Not I site of ecCytTs-cEPO and pCytTs-EGFP, respectively.

[00193] Initial experiments were performed with a construct in which a slightly truncated form of OriP had been subcloned into pCytTs-EGFP. pCep4 (Invitrogen) was digested with Dra III and Nsi I and the 1923 nucleotide fragment (position 200-2124 from pCep4) was then treated with T4 polymerase in order to get blunt ends. The blunted fragment was then subcloned into pCytTs-EGFP, which had previously been digested with Not I and blunted with T4 DNA polymerase. The resulting plasmid was termed pCytTs-EGFP-OriPd.

B. Analysis of pCytTs-EGFP-OriPd in 293 EBNA cells

[00194] We first analyzed whether the introduction of Epstein-Barr virus derived origin of replication (OriP) into the pCytTs system would improve the inducible expression of a gene of interest on selected cell populations. We therefore transfected 293-EBNA cells (Invitrogen) with pCytTs-EGFP-OriPd. These cells constitutively express Epstein-Barr virus replication initiation factor EBNA1 and support OriP mediated DNA replication. 293-EBNA cells were transfected with pCytTs-EGFP-OriPd using Lipofectamine 2000 (BRL) according to the manufacturer's recommendation. 36h after transfection cells were split 1 to 3 in presence of 1µg/ml puromycin. After 1 to 2 days all non-transfected cells had detached and the resistant cells were further expanded under puromycin selection for another week. In order to assess the expression from the new vector, resistant cell populations were passed to two plates of which one was kept at 37°C (uninduced) and one was shifted to 29°C for induction of EGFP expression. 24h after induction cells were harvested by trypsinisation and analysed by flow cytometry (Fig. 3). Upon induction cell populations carrying pCytTs-EGFP-OriPd were to 80% EGFP positive and displayed strong EGFP expression. In contrast cells, which had not been induced showed only weak EGFP expression and only about 8% of the cells, were green. Considering that stable cell populations containing CytTs-EGFP would only yield about 2-5% EGFP positive cells upon induction (data not shown) these results suggest that the OriP, which was introduced in the new vector, is functional and that it significantly improves the number of cells in a cell population, which expresses the gene of interest.

C. Comparison of pCytTs-EGFP, pCytTs-EGFP-OriP and pCytTs-EGFP-OPE in BHK cells

[00195] The following constructs, pCytTs-EGFP, pCytTs-EGFP-OriP and pCytTs-EGFP-OPE, were next examined in BHK (Baby hamster kidney) cells

which are known to show tight regulation for the CytTs system. BHK cells were transfected with CytTs-EGFP, CytTs-EGFP-OriP and CytTs-EGFP-OPE using Lipofectamine 2000 (BRL) according to the manufacturer's recommendation. 24h after transfection cells were split 1 to 3 in presence of 5µg/ml puromycin. After 2 to 3 days all non-transfected cells had detached and the resistant cells were further expanded under puromycin selection for another week. Resistant cell populations were passed to two plates of which one was kept at 37 °C (non-induced) and one was shifted to 29 °C for induction of replicon replication and EGFP expression. Three days after induction cells were harvested and analysed by flow cytometry (Fig. 4). About 20% of the cell populations carrying CytTs-EGFP or CytTs-EGFP-OriP were EGFP positive upon induction, whereas four times more cells - up to 90% of the cells transfected with CytTs-EGFP-OPE did express EGFP after temperature induction. Thus, the inventive expression systems turned out to be very tight since less than 0.5% of the uninduced population showed weak EGFP expression.

D. Inducible expression of pCytTs-IFNβ-OPE and pCytTs-SEAP-OPE in BHK cells

[00196] We further analyzed constructs which contain both OriP and the replication initiation factor EBNA1 (pCytTs-IFNβ-OPE) with other genes of interest in BHK cells. These constructs do not depend on cell lines which have an integrated copy of the EBNA1 gene. As a gene of interest we choose IFNβ, which had already been expressed with the conventional CytTs system. To test whether our new vector system with its episomal replication could result in high, inducible levels of expression on selected cell populations we transfected BHK cells with pCytTs-IFNβ-OPE (*see* Example 2A) using Lipofectamine 2000 (BRL) according to the manufacturer's recommendation. 36h after transfection cells were split 1 to 3 in the presence of 5µg/ml puromycin. After 1 to 2 days all non-transfected cells had detached and the

resistant cells were further expanded under puromycin selection for another 1 - 2 weeks. In order to assess the expression from the new vector, resistant cell populations were passed to two plates one of which was kept at 37°C (uninduced) and one was shifted to 29°C for induction of IFN β expression. Tissue culture supernatants were harvested from the uninduced control plate and 3, 4, 7 and 9 day after induction from the plate that had been shifted to 29 °C. The IFN β production at the different time points was then quantitated by ELISA (Kit of Fujirebio Inc., Tokyo, Japan). The induced cell populations reached a maximal level of 1,000,000 IU/ml after 7-9 days of induction and no IFN production could be detected in cells kept at non-permissive temperature (Figs. 3A-3B). These results show that our new vector system combining the CytTs system with the episomally replicating EBNA system leads to high production levels in BHK cells on selected populations. The expression levels are at least as high as the ones obtained from a stable cell clone, which resulted from 4 subcloning rounds (data not shown). In addition the new system is still tightly regulated as demonstrated by up to 300,000 fold induction observed upon shifting the cells to 29°C.

[00197] Besides IFN β production we also analysed SEAP production with our new vector system in BHK cells. Selected cell populations were generated as described under C using construct pCytTs-SEAP-OPE. After two weeks of selection and propagation the resistant cells were passed into two plates of which one was kept at 37°C and the other was shifted to 29°C for induction. Samples were taken from the uninduced cell populations and from the induced cell population 3, 4, 7 and 9 days after induction. SEAP concentrations were measured in these samples using a kinetic ELISA for SEAP activity. The results are shown in Fig. 6.

E. Comparison of the EPO production derived from pCytTs-OriP-EPO or with pCytTs-OPE-EPO in 293 EBNA cells

[00198] We further investigated whether an additional copy of the EBNA-1 gene on the same plasmid leads to higher expression of the gene of interest in 293-EBNA cells. 293-EBNA cells were transfected either with pCytTs-OriP-EPO or with pCytTS-OPE-EPO (see Example 2A) using Lipofectamin 2000 (BRL) according to the manufacturer's recommendation. One day after transfection the cells were split 1 to 2.5 in the presence of 0.8 µg/ml puromycin. A stable cell pool was obtained by further keeping these cells under selective pressure for one week. Resistant cell populations were then passed to two plates. Once the cells had attached, one plate was kept at 37°C and one plate was shifted to 29°C for induction. Cell culture supernatants were collected from both plates 4 and 8 days after induction. The erythropoietin (EPO) levels in the cell culture supernatants were then determined with an ELISA kit (R&D Systems, Minneapolis, USA). As shown in Fig. 7 the additional copy of the EBNA1 gene on the plasmid leads to a 15 to 20 fold increase in the EPO production compared to the plasmid which only contains the OriP. In conclusion, this experiment shows that, even in cells which contain an integrated copy, the expression of the gene of interest can be increased by an additional copy on the plasmid. These results suggest that the EBNA1 dosage may be a limiting factor for efficient replication to occur. In these experiments the EBNA1 dosage was increased by a copy on the OriP-containing plasmid. Similar results may be obtained if the EBNA1 dosage is increased in the cells either by the integration of further copies or if the additional copies would be provided on a separate plasmid in *trans*.

[00199] Having now fully described the present invention in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to one of ordinary skill in the art that the same can be performed by modifying or changing the invention within a wide and equivalent range of conditions, formulations and other parameters without

-57-

affecting the scope of the invention or any specific embodiment thereof, and that such modifications or changes are intended to be encompassed within the scope of the appended claims.

[00200] All publications, patents and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains, and are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.

WHAT IS CLAIMED IS:

1. A nucleic acid molecule comprising:
 - (A) a first polynucleotide element which encodes an RNA molecule, said RNA molecule comprising:
 - (a) at least one *cis*-acting sequence element;
 - (b) a first nucleotide sequence comprising a first open reading frame, said first open reading frame having a nucleotide sequence encoding an RNA-dependent RNA polymerase; and
 - (c) at least one second nucleotide sequence selected from the group consisting of:
 - (i) a second open reading frame encoding a polypeptide;
 - (ii) a nucleotide sequence complementary to all or a part of the second open reading frame of (i); and
 - (iii) a nucleotide sequence encoding an untranslated RNA molecule or complement thereof;wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said RNA-dependent RNA polymerase;
 - (B) a second polynucleotide element comprising an origin of replication; and
 - (C) a third polynucleotide element encoding a replication initiation factor capable of recognizing said origin of replication.
2. The nucleic acid molecule of claim 1, wherein said second open reading frame is in a translatable format after one or more RNA-dependent RNA replication events.
3. The nucleic acid molecule of claim 1, wherein said RNA-dependent RNA polymerase is selected from the group consisting of: (a) a temperature-sensitive RNA-dependent RNA polymerase; (b) a non-

cytopathic RNA-dependent RNA polymerase; and (c) a temperature-sensitive, non-cytopathic RNA-dependent RNA polymerase.

4. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from a prokaryotic organism or a eukaryotic organism.
5. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from a virus.
6. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from a DNA virus.
7. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from a DNA virus that allows for episomal replication.
8. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from a DNA virus selected from the group consisting of Papillomavirus, Polyomavirus, Adenovirus, and Hepadnaviruses.
9. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from a Herpesvirus.
10. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from Epstein-Barr virus (EBV).
11. The nucleic acid molecule of claim 10, wherein said origin of replication is *oriP*.

12. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from an eukaryotic organism selected from the group consisting of yeast, and insects.
13. The nucleic acid molecule of claim 1, wherein said origin of replication is derived from a mammal.
14. The nucleic acid molecule of claim 1, wherein said replication initiation factor is capable of operating as a plasmid maintenance factor.
15. The nucleic acid molecule of claim 1, wherein said replication initiation factor is derived from a prokaryotic organism or a eukaryotic organism.
16. The nucleic acid molecule of claim 1, wherein said replication initiation factor is derived from a virus.
17. The nucleic acid molecule of claim 1, wherein said replication initiation factor is derived from a DNA virus.
18. The nucleic acid molecule of claim 1, wherein said replication initiation factor is derived from a DNA virus selected from the group consisting of Herpesvirus, Papillomavirus, Polyomavirus, Adenovirus, and Hepadnavirus.
19. The nucleic acid molecule of claim 1, wherein said replication initiation factor is derived from a Herpesvirus.
20. The nucleic acid molecule of claim 1, wherein said replication initiation factor is derived from EBV.

-61-

21. The nucleic acid molecule of claim 20, wherein said replication initiation factor is the EBNA-1 protein.
22. The nucleic acid molecule of claim 1, wherein said replication initiation factor and said origin of replication are derived from the same organism or the same virus.
23. The nucleic acid molecule of claim 1, wherein said replication initiation factor and said origin of replication are derived from different organisms or viruses.
24. The nucleic acid molecule of claim 1 further comprising a fourth polynucleotide element, wherein said fourth polynucleotide element comprises a selection marker.
25. The nucleic acid molecule of claim 24, wherein said selection marker confers resistance to Puromycin.
26. The nucleic acid molecule of claim 1, wherein said RNA-dependent RNA polymerase is of viral origin.
27. The nucleic acid molecule of claim 1, wherein said RNA-dependent RNA polymerase is of alphaviral origin.
28. The nucleic acid molecule of claim 1, wherein said RNA-dependent RNA polymerase is derived from a Sindbis virus.
29. The nucleic acid molecule of claim 1, wherein said RNA-dependent RNA polymerase is derived from a Semliki Forest virus.
30. The nucleic acid molecule of claim 1, wherein said RNA-dependent RNA polymerase is derived from an Aura virus.

31. The nucleic acid molecule of claim 1, wherein said RNA-dependent RNA polymerase is derived from a virus selected from the group consisting of Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine encephalomyelitis virus, Fort morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus.
32. The nucleic acid molecule of claim 3, wherein said temperature-sensitive RNA-dependent RNA polymerase has replicase activity at temperatures below 34°C which is at least five fold greater than the replicase activity exhibited at 34°C or above.
33. The nucleic acid molecule of claim 3, wherein said temperature-sensitive RNA-dependent RNA polymerase has replicase activity at 34°C which is at least five fold lower than the replicase activity exhibited at 29°C.
34. The nucleic acid molecule of claim 1, wherein said second open reading frame encodes a cytokine, a lymphokine, a tumor necrosis factor, an interferon, a toxic polypeptide, a prodrug or a converting enzyme.
35. The nucleic acid molecule of claim 1, wherein said second open reading frame encodes human β -interferon.
36. The nucleic acid molecule of claim 1, wherein said second nucleotide sequence encodes an untranslated RNA molecule selected from the

group consisting of an antisense RNA molecule, a tRNA molecule, a rRNA molecule, and a ribozyme.

37. An expression system comprising:

- (A) a first polynucleotide element which encodes an RNA molecule, said RNA molecule comprising:
 - (a) at least one *cis*-acting sequence element;
 - (b) a first nucleotide sequence comprising a first open reading frame, said first open reading frame having a nucleotide sequence encoding an RNA-dependent RNA polymerase; and
 - (c) at least one second nucleotide sequence selected from the group consisting of:
 - (i) a second open reading frame encoding a polypeptide;
 - (ii) a nucleotide sequence complementary to all or a part of the second open reading frame of (i); and
 - (iii) a nucleotide sequence encoding an untranslated RNA molecule or complement thereof;wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said RNA-dependent RNA polymerase;
- (B) a second polynucleotide element comprising an origin of replication; and
- (C) a third polynucleotide element encoding a replication initiation factor capable of recognizing said origin of replication.

38. The expression system of claim 37, wherein said second open reading frame is in a translatable format after one or more RNA-dependent RNA replication events.

39. The expression system of claim 37, wherein said first, second and third polynucleotide elements are DNA elements.
40. The expression system of claim 37, wherein said first, second and third polynucleotide elements are each present on a separate nucleic acid molecule.
41. The expression system of claim 37, wherein said first, second and third polynucleotide elements are all present on a single nucleic acid molecule.
42. The expression system of claim 37, wherein said first and said second polynucleotide elements are present on a first nucleic acid molecule, and said third polynucleotide element is present on a second nucleic acid molecule.
43. The expression system of claim 42, wherein said second nucleic acid molecule further comprises a fourth polynucleotide element capable of promoting the replication of said second nucleic acid molecule.
44. The expression system of claim 42, wherein said second nucleic acid sequence further comprises an origin of replication.
45. The expression system of claim 37, wherein said RNA-dependent RNA polymerase is selected from the group consisting of: (a) a temperature-sensitive RNA-dependent RNA polymerase; (b) a non-cytopathic RNA-dependent RNA polymerase; and (c) a temperature-sensitive, non-cytopathic RNA-dependent RNA polymerase.
46. The expression system of claim 37, wherein said origin of replication is derived from a prokaryotic organism or a eukaryotic organism.

47. The expression system of claim 37, wherein said origin of replication is derived from a virus.
48. The expression system of claim 37, wherein said origin of replication is derived from a DNA virus.
49. The expression system of claim 37, wherein said origin of replication is derived from a DNA virus that allows for episomal replication.
50. The expression system of claim 37, wherein said origin of replication is derived from a DNA virus selected from the group consisting of Herpesvirus, Papillomavirus, Polyomavirus, Adenovirus, and Hepadnaviruses.
51. The expression system of claim 37, wherein said origin of replication is derived from a Herpesvirus.
52. The expression system of claim 37, wherein said origin of replication is derived from Epstein-Barr virus (EBV).
53. The expression system of claim 52, wherein said origin of replication is *oriP*.
54. The expression system of claim 37, wherein said origin of replication is derived from an eukaryotic organism selected from the group consisting of yeast, insects and mammals.
55. The expression system of claim 37, wherein said origin of replication is derived from a mammal.
56. The expression system of claim 37, wherein said replication initiation factor is capable of operating as plasmid maintenance factor.

57. The expression system of claim 37, wherein said replication initiation factor is derived from a prokaryotic organism or a eukaryotic organism.
58. The expression system of claim 37, wherein said replication initiation factor is derived from a virus.
59. The expression system of claim 37, wherein said replication initiation factor is derived from a DNA virus.
60. The expression system of claim 37, wherein said replication initiation factor is derived from a DNA virus selected from the group consisting of Herpesvirus, Papillomavirus, Polyomavirus, Adenovirus, and Hepadnavirus.
61. The expression system of claim 37, wherein said replication initiation factor is derived from a Herpesvirus.
62. The expression system of claim 37, wherein said replication initiation factor is derived from EBV.
63. The expression system of claim 37, wherein said replication initiation factor is the EBNA-1 protein, or portion thereof.
64. The expression system of claim 37, wherein said replication initiation factor and said origin of replication are derived from the same organism or the same virus.
65. The expression system of claim 37, wherein said replication initiation factor and said origin of replication are derived from different organisms.

66. The expression system of claim 37, further comprising a fourth polynucleotide element, wherein said fourth polynucleotide element comprises a selection marker.
67. The expression system of claim 66, wherein said selection marker confers resistance to Puromycin.
68. The expression system of claim 37, wherein said RNA-dependent RNA polymerase is of viral origin.
69. The expression system of claim 37, wherein said RNA-dependent RNA polymerase is of alphaviral origin.
70. The expression system of claim 37, wherein said RNA-dependent RNA polymerase is derived from a Sindbis virus.
71. The expression system of claim 37, wherein said RNA-dependent RNA polymerase is derived from a Semliki Forest virus.
72. The expression system of claim 37, wherein said RNA-dependent RNA polymerase is derived from an Aura virus.
73. The expression system of claim 37, wherein said RNA-dependent RNA polymerase is derived from a virus selected from the group consisting of Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine encephalomyelitis virus, Fort morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus.

74. The expression system of claim 45, wherein said temperature-sensitive RNA-dependent RNA polymerase has replicase activity at temperatures below 34°C which is at least five fold greater than the replicase activity exhibited at 34°C or above.
75. The expression system of claim 45, wherein said temperature-sensitive RNA-dependent RNA polymerase has replicase activity at 34°C which is at least five fold lower than the replicase activity exhibited at 29°C.
76. The expression system of claim 37, wherein said second open reading frame encodes a cytokine, a lymphokine, a tumor necrosis factor, an interferon, a toxic protein, a prodrug or a converting enzyme.
77. The expression system of claim 37, wherein said second open reading frame encodes human β -interferon.
78. The expression system of claim 37, wherein said second nucleotide sequence encodes an untranslated RNA molecule selected from the group consisting of an antisense RNA molecule, a tRNA molecule, a rRNA molecule, and a ribozyme.
79. A method of making a recombinant host cell comprising introducing the nucleic acid molecule of claim 1 into a host cell.
80. The method of claim 79, wherein said RNA-dependent RNA polymerase is selected from the group consisting of: (a) a temperature-sensitive RNA-dependent RNA polymerase; (b) a non-cytopathic RNA-dependent RNA polymerase; and (c) a temperature-sensitive, non-cytopathic RNA-dependent RNA polymerase.

81. The method of claim 79, wherein said nucleic acid molecule is introduced by way of transfection.
82. A method of making a recombinant host cell comprising introducing the expression system of claim 37 into a host cell.
83. The method of claim 82, wherein said RNA-dependent RNA polymerase is selected from the group consisting of: (a) a temperature-sensitive RNA-dependent RNA polymerase; (b) a non-cytopathic RNA-dependent RNA polymerase; and (c) a temperature-sensitive, non-cytopathic RNA-dependent RNA polymerase.
84. The method of claim 82, wherein said expression system is introduced by way of transfection.
85. A recombinant host cell produced by the method of claim 79.
86. A recombinant host cell produced by the method of claim 82.
87. A recombinant host cell comprising:
 - (A) a first polynucleotide element which encodes an RNA molecule, said RNA molecule comprising:
 - (a) at least one *cis*-acting sequence element;
 - (b) a first nucleotide sequence comprising a first open reading frame, said first open reading frame having a nucleotide sequence encoding an RNA-dependent RNA polymerase; and
 - (c) at least one second nucleotide sequence selected from the group consisting of:
 - (i) a second open reading frame encoding a polypeptide;

- (ii) a nucleotide sequence complementary to all or a part of the open reading frame of (i); and
- (iii) a nucleotide sequence encoding an untranslated RNA molecule or complement thereof;

wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said RNA-dependent RNA polymerase;

- (B) a second polynucleotide element comprising an origin of replication; and
 - (C) a third polynucleotide element encoding a replication initiation factor capable of recognizing said origin of replication.
88. The recombinant host cell of claim 87, wherein said second open reading frame is in a translatable format after one or more RNA-dependent RNA replication events.
89. The recombinant host cell of claim 87, wherein said first, second and third polynucleotide elements are DNA elements.
90. The recombinant host cell of claim 87, wherein said third polynucleotide is stably integrated into the genome of said host cell.
91. The recombinant host cell of claim 87, wherein said first and said second polynucleotide elements are present on a first nucleic acid molecule, and said third polynucleotide element is present on a second nucleic acid molecule.
92. The recombinant host cell of claim 87, further comprising a fourth polynucleotide comprising a selection marker.
93. The recombinant host cell of claim 92, wherein said selection marker confers resistance to Puromycin.

94. The recombinant host cell of claim 91, wherein said second nucleic acid molecule further comprises a fifth polynucleotide element capable of promoting the replication of said second nucleic acid molecule.
95. The recombinant host cell of claim 91, wherein said nucleotide sequence further comprises an origin of replication.
96. The recombinant host cell of claim 87, wherein said first, second and third polynucleotide elements are provided on the same nucleic acid molecule.
97. The recombinant host cell of claim 87, wherein said RNA-dependent RNA polymerase is selected from the group consisting of: (a) a temperature-sensitive RNA-dependent RNA polymerase; (b) a non-cytopathic RNA-dependent RNA polymerase; and (c) a temperature-sensitive, non-cytopathic RNA-dependent RNA polymerase.
98. The recombinant host cell of claim 87, wherein said recombinant host cell is a mammalian cell.
99. The recombinant host cell of claim 98, wherein said mammalian cell is selected from the group consisting of a human cell, a primate cell and a rodent cell.
100. The recombinant host cell of claim 87, wherein said host cell comprises more than one copy of said third polynucleotide.
101. The recombinant host cell of claim 100, wherein at least one copy of said third polynucleotide is stably integrated into the genome of said host cell.

102. A method for producing a polypeptide or untranslated RNA molecule, said method comprising:
- (a) introducing the nucleic acid molecule of claim 1 into a host cell to produce a recombinant host cell; and
 - (b) culturing said recombinant host cell under conditions suitable for expression of said polypeptide or untranslated RNA molecule.
103. The method of claim 102, further comprising recovering said polypeptide or untranslated RNA molecule.
104. A method for producing a polypeptide or untranslated RNA molecule, said method comprising:
- (a) introducing the expression system of claim 37 into a host cell to produce a recombinant host cell; and
 - (b) culturing said recombinant host cell under conditions suitable for expression of said polypeptide or untranslated RNA molecule.
105. The method of claim 104, further comprising recovering said polypeptide or untranslated RNA molecule.
106. A method for regulating the expression of a polypeptide or an untranslated RNA molecule, said method comprising:
- (a) introducing the nucleic acid molecule of claim 3 into a host cell to produce a recombinant host cell;
 - (b) growing said recombinant host cell under suitable culture conditions; and
 - (c) changing the temperature of the recombinant host cell culture from:
 - (i) a permissive temperature to a restrictive temperature, or
 - (ii) a restrictive temperature to a permissive temperature;

wherein said polypeptide or untranslated RNA molecule is encoded by said first polynucleotide.

107. The method of claim 106, wherein said polypeptide is a polypeptide that is toxic to said host cell.
108. A method for regulating the expression of a polypeptide or an untranslated RNA molecule, said method comprising:
- (a) introducing the expression system of claim 45 into a host cell to produce a recombinant host cell;
 - (b) growing said recombinant host cell under suitable culture conditions; and
 - (c) changing the temperature of the recombinant host cell culture from:
 - (i) a permissive temperature to a restrictive temperature, or
 - (ii) a restrictive temperature to a permissive temperature;
- wherein said polypeptide or untranslated RNA molecule is encoded by said first polynucleotide.
109. The method of claim 108, wherein said polypeptide is a polypeptide that is toxic to said host cell.

GENE EXPRESSION SYSTEM

ABSTRACT OF THE DISCLOSURE

The present invention relates to compositions and methods that allow the production of polypeptides and untranslated RNA molecules in host cells. More specifically, the invention provides nucleic acid molecules, expression systems, recombinant host cells, methods and kits, which enable the production and/or isolation and/or purification of polypeptides and untranslated RNA molecules. The compositions and methods of the invention can be applied in a regulatable expression system that is transiently transfected into mammalian host cells.

47068.1




Fig. 1

CTGACGCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCC
CTAGCGCCCGCTCCTTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTGCGCCGCTTTCCCCGTCAAGCTCTAAATCGGGG
GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCAAAAAAGTTGATTAGGGTGATGGTTCACCTAGTG
GGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACT
GGAACAACACTCAACCCTATCTCGGTCTATCTTTTGATTTATAAGGGATTTTGCCGATTTGCGGCTATTGGTTAAAAAA
TGAGCTGATTTAAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTCCATTGCGCCATTCAGGCTGCG
CAACTGTTGGGAAGGGCGATCGGTGCGGGCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGAT
TAAGTTGGGTAAACGCCAGGGTTTTCCAGTCACGACGTTGTAAAACGACGGCCAGTGAgcgcgcaattaaccctcactaa
agggaaacaaaagctggctagtGATCCAGTCTTATGCAATACTCTTGAGTCTTGCAACATGGTAACGATGAGTTAGCAA
CATGCCCTTACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAAGTAAGGTGGTACGATCGTGCCTTATTAGGAAG
GCAACAGACGGGTCTGACATGGATTGGACGAACCACTGAATTCGCGATTGCAGAGATATTGTATTTAAGTGCCCTACCTc
gataccgTCGAGATTGACGGCGTAGTACACACTATTGAATCAACAGCCGACCAATTGCACCTACCATCACAATGGAGAAG
CCAGTAGTAAACGTAGACGTAGACCCCCAGAGTCCGTTTGTGCTGCAACTGCAAAAAAGCTTCCGCAATTTGAGGTAGT
AGCACAGCAGGTCCTCCAAATGACCATGCTAATGCCAGAGCATTTCGCATCTGGCCAGTAACTAATCGAGCTGGAGG
TTCCTACCACAGCGACGATCTTGACATAGGCAGCGCACCGGCTCGTAGAATGTTTTCCGAGCACCAGTATCATTGTGTC
TGCCCCATGCGTAGTCCAGAAGACCCGGACCGCATGATGAAATACGCCAGTAACTGGCGGAAAAAGCGTGCAAGATTAC
AAACAAGAACTTGATGAGAAGATTAAAGGATCTCCGACCGTACTTGATACGCCGGATGCTGAAACACCATCGCTCTGCT
TTCACAACGATGTTACCTGCAACATGCGTGCCGAATATTCGTCATGCAGGACGTGTATATCAACGCTCCCGGAACTATC
TATCATCAGGCTATGAAAGCGTGCGGACCCCTGTACTGGATTGGCTTCGACACCAACCCAGTTCATGTTCTCGGCTATGGC
AGGTTGCTACCTGCGTACAACACCAACTGGGCCGACGAGAAAGTCTTGAAGCGCGTAACATCGGACTTTGCAGCACAA
AGCTGAGTGAAGGTAGGACAGGAAAATTGTGATAATGAGGAAGAAGGAGTTGAAGCCCGGGTTCGCGGGTTTATTTCTCC
GTAGGATCGACACTTTATCCAGAACACAGAGCCAGCTTGAGAGCTGGCATCTTCCATCGGTGTTCCACTTGAATGGAAA
GCAGTCGTACACTTGCCGCTGTGATACAGTGGTGAGTTGCGAAGGCTACGTAGTGAAGAAAATCACCATCAGTCCCGGGA
TCACGGGAGAAACCGTGGGATACGCGGTTACACACAATAGCGAGGGCTTCTTGCTATGCAAAGTTACTGACACAGTAAAA
GGAGAACGGGTATCGTTCCCTGTGTGCACGTACATCCCGGCCACCATATGCGATCAGATGACTGGTATAATGGCCACGGA
TATATCACCTGACGATGCACAAAAAATCTTGTTGGGGCTCAACCAGCGAATTGTCTTAAACGGTAGGACTAACAGGAACA
CCAACACCATGCAAAATTACCTTCTGCCGATCATAGCACAAGGGTTCAGCAAATGGGCTAAGGAGCGCAAGGATGATCTT
GATAACGAGAAAAATGCTGGGTACTAGAGAACGCAAGCTTACGTATGGCTGCTTGTGGGCGTTTCGCACTAAGAAAAGTACA
TTCGTTTTATCGCCACCTGGAACGCAGACCTGCGTAAAAGTCCAGCCTCTTTAGCGCTTTTCCCATGTGCTCCGTAT
GGACGACCTCTTTGCCCATGTGCTGAGGCAGAAATTGAACTGGCATTGCAACCAAGAAGGAGGAAAAAAGTGTGTCAG
GTCTCGGAGGAATTAGTCATGGAGGCCAAGGCTGCTTTGAGGATGCTCAGGAGGAAGCCAGAGCGGAGAAGCTCCGAGA
AGCACTTCCACCATTAGTGGCAGACAAAGGCATCGAGGCAGCGCAGAAGTTGTCTGCGAAGTGGAGGGGCTCCAGGCGG
ACATCGGAGCAGCATTAGTTGAAACCCCGCGCGGTACGTAAGGATAATACCTCAAGCAAATGACCGTATGATCGGACAG
TATATCGTTGTCTCGCCAAACTCTGTGCTGAAGAATGCCAACTCGCACCAGCGCACCCGCTAGCAGATCAGGTTAAGAT
CATAACACACTCCGGAAGATCAGGAAGGTACGCGGTGCAACCATACGACGCTAAAGTACTGATGCCAGCAGGAGGTGCCG
TACCATGGCCAGAATTCTAGCACTGAGTGAGAGCGCCACGTTAGTGTAACGAAAGAGAGTTTGTGAACCGCAAATA
TACCACATTGCCATGCATGGCCCGCCAAGAATACAGAAGAGGAGCAGTACAAGGTTACAAAGGCAGAGCTTGCAAGAAC
AGAGTACGTGTTTGACGTGGACAAGAAGCGTTGCGTTAAGAAGGAAGAAGCCTCAGGTCTGGTCTCTCGGGAGAACTGA
CCAACCTCCCTATCATGAGCTAGCTCTGGAGGGACTGAAGACCCGACCTGCGGTCCCGTACAAGGTGCAACCAATAGGA
GTGATAGGCACACCGGGGTCGGGCAAGTCAGCTATTATCAAGTCAACTGTACGGCACGAGATCTTGTTACCAGCGGAAA
GAAAGAAAATTGTGCGGAAATTGAGGCCGACGTGCTAAGACTGAGGGGTATGCAGATTACGTGCAAGACAGTAGATTTCGG
TTATGCTCAACGGATGCCACAAAGCCGTAGAAGTGTGTACGTTGACGAAGCGTTGCGGTGCCACGCGAGGACACTACTT
GCCTTGATTGCTATCGTCAGGCCCCGCAAGAAGGTAGTACTATGCGGAGACCCCATGCAATGCGGATTCTTCAACATGAT
GCAACTAAAGGTACATTTCAATCACCCCTGAAAAAGACATATGCACCAAGACATTCTACAAGTATATCTCCCGCGGTGCA

Fig. 2A

CACAGCCAGTTACAGCTATTGTATCGACACTGCATTACGATGGAAAGATGAAAACCACGAACCCGTGCAAGAAGAACATT
GAAATCGATATTACAGGGGCCACAAAGCCGAAGCCAGGGGATATCATCTGACATGTTTCCGCGGGTGGGTTAAGCAATT
GCAAATCGACTATCCCGGACATGAAGTAATGACAGCCGCGGCCCTACAAGGGCTAACCAGAAAAGGAGTGTATGCCGTCC
GGCAAAAAGTCAATGAAAACCCACTGTACGCGATCACATCAGAGCATGTGAACGTGTTGCTCACC CGCACTGAGGACAGG
CTAGTGTGGAAAACCTTGCAGGGCGACCCATGGATTAAGCAGCCCACTAACATACCTAAAGGAACTTTTCAGGCTACTAT
AGAGGACTGGGAAGCTGAACACAAGGGAATAATTGCTGCAATAAACAGCCCCACTCCCCGTGCCAATCCGTTTCAGCTGCA
AGACCAACGTTTGCTGGGCGAAAGCATTGGAACCGATACTAGCCACGGCCGGTATCGTACTTACCGGTTGCCAGTGGAGC
GAACTGTTCCCAACAGTTTGCGGATGACAAACCACATTTCGGCCATTTACGCCTTAGACGTAATTTGCATTAAGTTTTTCGG
CATGGACTTGACAAGCGGACTGTTTTCTAAACAGAGCATCCCACTAACGTACCATCCCGCCGATTTCAGCGAGGCCGGTAG
CTCATTGGGACAACAGCCCAGGAACCCGCAAGTATGGGTACGATCACGCCATTGCGCGCGAACTCTCCCGTAGATTTCCG
GTGTTCCAGCTAGCTGGGAAGGGCACACAACCTTGATTTGCAGACGGGGAGAACCAGAGTTATCTCTGCACAGCATAACCT
GGTCCCGGTGAACCGCAATCTTCTCACGCCTTAGTCCCGAGTACAAGGAGAAGCAACCCGGCCCGGTCAAAAAATTCT
TGAACAGTTCAAACACCACTCAGTACTTGTGGTATCAGAGGAAAAAATTGAAGCTCCCCGTAAGAGAATCGAATGGATC
GCCCGATTGGCATAGCCGGTGCAGATAAGAACTACAACCTGGCTTTCCGGGTTTCCGCCGAGGCACGGTACGACCTGGT
GTTTCATCAACATTGGAACATAATACAGAAACCACCACTTTTCAGCAGTGCGAAGACCATGCGGCGACCTTAAAAACCTTT
CGCGTTCCGGCCCTGaatTgTtAaacTcaggaggcacCCTCGTGGTGAAGTCTATGGCTACGCCGACCGCAACAGTGAG
GACGTAGTCACCGCTCTTGCCAGAAAGTTTGTGAGGGTGTCTGCAGCGAGACCAGATTGTGTCTCAAGCAATACAGAAAT
GTACCTGATTTTCCGACAACCTAGACAACAGCCGTACAGCGCAATTCACCCCGCACCATCTGAATTGCGTGATTTTCGTCCG
TGTATGAGGGTACAAGAGATGGAGTTGGAGCCGCGCCGTATACCGCACCAAAAGGGAGAATATTGCTGACTGTCAAGAG
GAAGCAGTTGTCAACGCAGCCAATCCGCTGGGTAGACCAGGCGAAGGAGTCTGCCGTGCCATCTATAAACGTTGGCCGAC
CAGTTTTACCGATTTCAGCCACGGAGACAGGCACCGCAAGAATGACTGTGTGCTAGGAAAGAAAGTGATCCACGCGGTG
GCCCTGATTTCCGGAAGCACCCAGAAGCAGAAGCCTTGAAATTGCTACAAAACGCCTACCATGCAGTGGCAGACTTAGTA
AATGAACATAACATCAAGTCTGTGCCATTCCACTGCTATCTACAGGCATTTACGCAGCCGAAAAGACCGCCTTGAAGT
ATCACTTAAGTGTGACAACCGCGCTAGACAGAACTGACGCGGACGTAACCATCTATTGCCTGGATAAGAAGTGGAAGG
AAAGAATCGACGCGGCACTCCAACCTTAAGGAGTCTGTAACAGAGCTGAAGGATGAAGATATGGAGATCGACGATGAGTTA
GTATGGATTTCATCCAGACAGTTGCTTGAAGGGAAGAAAGGGATTGAGTACTACAAAAGGAAAATTGTATTGCTACTTCGA
AGGCACCAAATTCATCAAGCAGCAAAAGACATGGCGGAGATAAAGGTCCTGTTCCCTAATGACCAGGAAAGTAATGAAC
AACTGTGTGCTACATATTGGGTGAGACCATGGAAGCAATCCGCGAAAAGTGCCCGGTGACCCATAACCCGTCGTCTAGC
CCGCCCCAAACGTTGCCGTGCCCTTTGCATGTATGCCATGACGCCAGAAAGGTTCCACAGACTTAGAAGCAATAACGTCAA
AGAAGTTACAGTATGCTCCTCCACCCCCCTTCTTAAGCACAAAATTAAGAATGTTTCAAGAGGTTGAGTGCACGAAAGTAG
TCCTGTTTAAATCCGCACACTCCCGCATTCGTTCCCGCCGTAAGTACATAGAAGTGCCAGAACAGCCTACCGCTCCTCCT
GCACAGGCCGAGGAGGCCCCGAAGTTGTAGCGACACCGTCACCATCTACAGCTGATAACACCTCGCTTGATGTACAGA
CATCTCACTGGATATGGATGACAGTAGCGAAGGCTCACTTTTTTCGAGCTTTAGCGGATCGGACAACCTCTATTACTAGTA
TGGACAGTTGGTCGTGAGGACCTAGTTCACTAGAGATAGTAGACCGAAGGCAGGTGGTGGTGGCTGACGTTTCATGCCGTC
CAAGAGCCTGCCCCATTCCACCGCCAAGGCTAAAGAAGATGGCCCGCTGGCAGCGGCAAGAAAAGAGCCCACTCCACC
GGCAAGCAATAGCTCTGAGTCCCTCCACCTCTCTTTGGTGGGGTATCCATGTCCCTCGGATCAATTTTCGACGGAGAGA
CGGCCCGCCAGGCAGCGGTACAACCCCTGGCAACAGGCCCCACGGATGTGCCTATGTCTTTTCGGATCGTTTTCCGACGGA
GAGATTGATGAGCTGAGCCGAGAGTAAGTGAAGTCCGAACCCGTCCTGTTTGGATCATTTGAACCGGGCGAAGTGAAGTC
AATTTATATCGTCCCGATCAGCCGTATCTTTTCCACTACGCAAGCAGAGACGTAGACGCGAGGAGCAGGAGGACTGAATACT
GACTAACCGGGGTAGGTGGGTACATATTTTCGACGGACACAGGCCCTGGGCACTTGCAAAAGAAGTCCGTTCTGCAGAAC
CAGCTTACAGAACCGACCTTGAGCGCAATGTCTGGAAAGAATTATGCCCGGTGCTCGACACGTCGAAAGAGGAACA
ACTCAAACCTCAGGTACCAGATGATGCCCCACCGAAGCCAACAAAAGTAGGTACCAGTCTCGTAAAGTAGAAAATCAGAAAG
CCATAACCACTGAGCGACTACTGTGAGGACTACGACTGTATAACTCTGCCACAGATCAGCCAGAATGCTATAAGATCACC
TATCCGAAACCATGTACTCCAGTAGCGTACCGGCGAACTACTCCGATCCACAGTTCCGCTGTAGCTGTCTGTAACAACCTA

Fig. 2B

TCTGCATGAGAAGTATCCGACAGTAGCATCTTATCAGATTACTGACGAGTACGATGCTTACTTGGATATGGTAGACGaGA
CAGTCGCaTGCCTGGATACTGCAACCTTCTGCCCGCTAAGCTTAGAAGTTACCCGAAAAAACATGAGTATAGAGCCCCG
AATATCCGCAGTGCCTTCCATCAGCGATGCAGAACACGCTACAAAATGTGCTCATTGCCGCAACTAAAAGAAATTGCAA
CGTCACGCAGATGCGTGAAGTCCAAACACTGGACTCAGCGACATTCAATGTGCAATGCTTTCGAAAAATGTCATGTAATG
ACGAGTATTGGGAGGAGTTCGCTCGGAAGCCAATTAGGATTACCACTGAGTTTGTACCCGCATATGTAGCTAGACTGAAA
GGCCCTAAGGCCGCCGCACTATTTGCAAAGACGTATAATTTGGTCCATTGCAAGAAGTGCCTATGGATAGATTTCGTAT
GGACATGAAAAGAGACGTGAAAGTTACACCAGGCACGAAACACACAGAAGAAAGACCGAAAGTACAAGTGATACAAGCCG
CAGAACCCCTGGCGACTGCTTACTTATGCGGGATTACCGGGAATTAGTGCCTAGGCTTACGGCCGCTTTCGCTTCCAAAC
ATTCACACGCTTTTTTGACATGTGCGCGGAGGATTTTGATGCAATCATAGCAGAACACTTCAAGCAAGGCGACCCGGTACT
GGAGACGGATATCGCATCATTCGACAAAAGCCAAGACGACGCTATGGCGTTAACCGGTCTGATGATCTTGGAGGACCTGG
GTGTGGATCAACCACTACTCGACTTGATCGAGTGCCTTTGGAGAAATATCATCCACCCATCTACCTACGGGTACTCGT
TTTAAATTCGGGGCGATGATGAAATCCGGAATGTTCTCACACTTTTTGTCAACACAGTTTTGAATGTCGTTATCGCCAG
CAGAGTACTAGAAGAGCGGCTTAAAACGTCCAGATGTGCAGCGTTCATTGGCGACGACAACATCATACATGGAGTAGTAT
CTGACAAAAGAAATGGCTGAGAGGTGCGCCACCTGGCTCAACATGGAGGTTAAGATCATCGACGCAGTCATCGGTGAGAGA
CCACCTTACTTCTGCGGCGGATTATCTTGCAAGATTGCGTTACTTCCACAGCGTGCCGCGTGGCGGATCCCTGAAAAG
GCTGTTAAGTTGGGTAAACCGCTCCCAGCCGACGACGAGCAAGACGAAGACAGAAGACGCGCTCTGCTAGATGAAACAA
AGGCGTGGTTTAGAGTAGGTATAACAGGCACCTTTAGCAGTGGCCGTGACGACCCGGTATGAGGTAGACAATATTACACCT
GTCCTACTGGCATTGAGAAGTTTTGCCAGAGCAAAAGAGCATTCCAAGCCATCAGAGGGGAAATAAAGCATCTCTACGG
TGGTCTTAATAGTCAGCATAGTACATTTTCATCTGACTAATACTACAACACCACCACCTctagaCGCGTAGAtctcaggt
gagcatgcaggccttgggCCCAATGATCCGACCAGCAAACTCGATGTACTTCCGAGGAAGTATGTGCATAATGCATCA
GGCTGGTACATTAGATCCCCGCTTACCGCGGGCAATATAGCAACACTAAAACTCGATGTACTTCCGAGGAAGCGCAGTG
CATAATGCTGCGCAGTGTGCCACATAACCACTATATTAACCATTTATCTAGCGGACGCCAAAACTCAATGTATTTCTG
AGGAAGCGTGGTGCATAATGCCACGCAGCGTCTGCATAACTTTTATTATTTCTTTTATTAATCAACAAAATTTTGTTTTT
AACATTTCAAAAAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAA
CTCATCAATGTATCTTATCATGTCTGGATCCGTCGAGACGCGTccaattcgccctatagtgagtcgtattacgcgcgctT
GGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATGTTATCCGCTCACAAATCCACACAACATACGAGCCGGAAGCA
TAAAGTGTAAGCCTGGGGTGCCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCGCTTTCCAGTCG
GGAAACCTGTCTGTCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCCTATTGGGCGCTCTTCCGC
TTCTCTGCTCACTGACTCGCTGCGCTCGTCTGCGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGT
TATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCC
GCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAA
CCCGACAGGACTATAAAGATAACAGGCGTTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTA
CCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCCGGTG
TAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTACGCCGACCGCTGCGCCTTATCCGGTAACCTATCG
TCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATG
TAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTG
CTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACACCGCTGGTAGCGGTGGTTTTTT
TGTTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTC
AGTGGAACGAAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATTAA
AAATGAAGTTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACC
TATCTCAGCGATCTGTCTATTTCTGTTTATCCATAGTTGCTGACTCCCCGCTGCTGTAGATAACTACGATACGGGAGGGCT
TACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTACCGGCTCCAGATTTATCAGCAATAAACCAGCCA
GCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAG

Fig. 2C

AGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTG
 GTATGGCTTCATTCACTCCGGTTCCTAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGC
 TCCTTCGGTCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTC
 TCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGC
 GCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCAT
 GGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACC
 CAACTGATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGG
 GAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTATCAGGGTTATTGT
 CTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCGCGCACATTTCCTCCGAAAAGTGCC
 AC

Fig. 2D




Fig.3




Fig. 4




Fig. 5





Fig. 6

**FIG. 7**

CTGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGA
 CCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCTTTCGCTTCTTCCCTTCTTTCTCG
 CCACGTTTCGCGCGGATCCGCGCCATTAGCCATATTATTCATTGGTTATATAGCATAAAT
 CAATATTGGCTATTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATAT
 TGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTA
 ATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTAC
 GGTAATGGCCCCGCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGAC
 GTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTT
 ACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT
 TGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACCTTATGGGA
 CTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTT
 TTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGAATCACGGGGATTTCCTCAAGTCTCCA
 CCCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATG
 TCGTAACAACTCCGCCCCATTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTA
 TATAAGCAGAGCTCGTTTAGTGAACCGTATTGACGGCGTAGTACACACTATTGAATCAAA
 CAGCCGACCAATTGCACTACCATCACAATGGAGAAGCCAGTAGTAAACGTAGACGTAGAC
 CCCCAGAGCTCGTTTGTCTGTGCAACTGCAAAAAGCTTCCCGCAATTTGAGGTTAGTAGCA
 CAGCAGGTCACTCCAAATGACCATGCTAATGCCAGAGCATTTTCGCATCTGGCCAGTAAA
 CTAATCGAGCTGGAGGTTTCTACACAGCGACGATCTTGGACATAGGCAGCGCACCGGCT
 CGTAGAATGTTTTCCGAGCACCAGTATCATTGTGTCTGCCCCATGCGTAGTCCAGAAGAC
 CCGGACCGCATGATGAAATATGCCAGTAACTGGCGGAAAAAGCGTGCAAGATTACAAAC
 AAGAACTTGCAATGAGAAGATTAAGGATCTCCGGACCGTACTTGATACGCCGGATGCTGAA
 ACACCATCGCTCTGCTTTCACAACGATGTTACCTGCAACATGCGTGCCGAATATTCCGTC
 ATGCAGGACGTGTATATCAACGCTCCCGGAACCTATCTATCATCAGGCTATGAAAGGCGTG
 CGGACCCCTGTACTGGATTGGCTTCGACACCACCCAGTTTCATGTTCTCGGCTATGGCAGGT
 TCGTACCCTGCGTACAACACCAACTGGGCGGACGAGAAAAGTCTTGAAGCGCGTAACATC
 GGACTTTGCAGCACAAAGCTGAGTGAAGGTAGGACAGGAAAATTGTGATAATGAGGAAG
 AAGGAGTTGAAGCCCCGGGTGCGCGGTTTATTTCTCCGTAGGATCGACACTTTATCCAGAA
 CACAGAGCCAGCTTGCAAGAGCTGGCATCTTCCATCGGTGTTCCACTTGAATGGAAAGCAG
 TCGTACACTTGCCGCTGTGATACAGTGGTGAGTTGCGAAGGCTACGTAGTGAAGAAAATC
 ACCATCAGTCCCGGATACGCGGAGAAACCGTGGGATACGCGGTTACACACAATAGCGAG
 GGCTTCTTGCTATGCAAAGTTACTGACACAGTAAAGGAGAACGCGGTATCGTTCCCTGTG
 TGCACGTACATCCCGGCCACCATATGCGATCAGATGACTGGTATAATGGCCACGGATATA
 TCACCTGACGATGCACAAAAACTTCTGGTTGGGCTCAACCAGCGAATTGTCAATTAACGGT
 AGGACTAACAGGAACACCAACACCATGCAAAATTACCTTCTGCCGATCATAGCACAAGGG
 TTCAGCAAAATGGGCTAAGGAGCGCAAGGATGATCTTGATAACGAGAAAATGCTGGGTACT
 AGAGAACGCAAGCTTACGTATGGCTGCTTGTGGGCGTTTCGCACTAAGAAAGTACATTCG
 TTTTATCGCCCACTGGAACGACAGCTCGCTGCTAAAAGTCCCAGCCTCTTTTAGCGCTTTT
 CCCATGTGCTCGTATGGACGACCTCTTGTCCCATGTGCTGAGGAGGAGAAATGAAACTG
 GCATTGCAACCAAGAAGGAGGAAAAACTGCTGCAGGTCTCGGAGGAATTAGTCATGGAG
 GCCAAGGCTGCTTTTGAAGGATGCTCAGGAGGAAGCCAGAGCGGAGAAAGCTCCGAGAAGCA
 CTTCCACCATTAGTGGCAGACAAAGGCATCGAGGACGCCGAGAAAGTTGTCTGCGAAGTG
 GAGGGGCTCCAGGCGGACATCGGAGCAGCATTAGTTGAAACCCCGCGCGGTACCGTAAGG
 ATAATACCTCAAGCAAATGACCGTATGATCGGACAGTATATCGTTGTCTCGCCAAACTCT
 GTGCTGAAGAATGCCAAACTCGCACGAGCGACCCGCTAGCAGATCAGGTAAAGATCATA
 ACACCTCCGGAAGATCAGGAAGGTACGCGGTGCAACCATACGACGCTAAAGTACTGATG
 CCAGCAGGAGGTGCCGTACCATGGCCAGAAATTCCTAGCACTGAGTGAGAGCGCCACGTTA
 GTGTACAACGAAAGAGAGTTTGTGAACCGCAAACTATACCACATTGCCATGCATGGCCCC
 GCCAAGAATACAGAAGAGGAGCAGTACAAGGTTACAAAGGCAGAGCTTGACAGAAACAGAG
 TACGTGTTTGACGTGGACAAGAAGCGTTGCGTTAAGAAGGAAGAAGCCTCAGGTCTGGTC
 CTCTCGGGAGAACTGACCAACCTCCCTATCATGAGCTAGCTCTGGAGGGACTGAAGACC
 CGACTGCGGTCCCGTACAAGGTGCAAAACAATAGGAGTGATAGGCACACCGGGGTGCGGC
 AAGTCAGCTATTATCAAGTCAACTGTCAAGGACGAGATCTTGTACCAGCGGAAAGAAA
 GAAAATTGTGCGGAAATTGAGGCGGAGCTGCTAAGACTGAGGGGTATGCAGATTACGTCG
 AAGACAGTAGATTTCGGTTATGCTCAACGGATGCCACAAAGCCGTAGAAGTGCTTACGTT
 GACGAAGCGTTGCGGTGCCACGAGGAGCACTACTTGCCTTGATTGCTATCGTCAGGCCC
 CGCAAGAAGGTAGTACTATGCGGAGACCCCATGCAATGCGGATTCTTCAACATGATGCAA
 CTAAGGTACATTTCAATCACCTGAAAAAGACATATGCACCAAGACATTCTACAAGTAT
 ATCTCCCGGCGTTGCACACAGCCAGTTACAGCTATTGTATCGCACTGCATACGATGGA
 AAGATGAAAACCAAGAACCCGTGCAAGAAGAACATTGAAATCGATATTACAGGGGCCACA

AAGCCGAAGCCAGGGGATATCATCCTGACATGTTTCCGCGGGTGGGTAAAGCAATTGCAA
 ATCGACTATCCCGGACATGAAGTAATGACAGCCGCGCTCACAAGGGCTAACAGAAAA
 GGAGTGTATGCCGTCCGGCAAAAAGTCAATGAAAACCCACTGTACGCGATCACATCAGAG
 CATGTGAACGTGTTGCTCACCCGCACTGAGGACAGGCTAGTGTGGAAAACCTTGCAGGGC
 GACCCATGGATTAAGCAGCTACTAACATACCTAAAGGAACTTTCAGGCTACTATAGAG
 GACTGGGAAGCTGAACACAAGGGAATAATTGCTGCAATAAACAGCCCCACTCCCCGTGCC
 AATCCGTTTCAGCTGCAAGACCAACGTTTGTGTTGGCGAAAGCAATTGGAACCGATACTAGCC
 ACGGCCGGTATCGTACTTACCGGTTGCCAGTGGAGCGAACTGTTCCACAGTTTGC GGAT
 GACAAACCACATTCGGCCATTTACGCCTTAGACGTAATTTGCATTAAAGTTTTTCGGCATG
 GACTTGACAAGCGGACTGTTTTCTAAACAGAGCATCCCACTAACGTACCATCCCGCCGAT
 TCAGCGAGGCCGGTAGCTCATTGGGACAACAGCCCAGGAACCCGCAAGTATGGGTACGAT
 CACGCCATTGCCGCCGAACCTCTCCCGTAGATTTCCGGTGTTCAGCTAGCTGGGAAGGGC
 ACACAACCTTGATTTGCAGACGGGGAGAACCAGAGTTATCTCTGCACAGCATAACCTGGTC
 CCGGTGAACCCGAATCTTCTCACGCCCTTAGTCCCCGAGTACAAGGAGAAGCAACCCGGC
 CCGGTGCAAAAATTCTTGAACCAAGTTCAAACACCACTCAGTACTTGTGGTATCAGAGGAA
 AAAATTGAAGCTCCCCGTAAGAGAATCGAATTGGATCGCCCCGATTGGCATAGCCGGTGCA
 GATAAGAAAGTGAACCTGGCTTTCGGGTTTCCGCGCAGGCACGGTACGACCTGTGTTT
 ATCAACATTGGAATAAATACAGAAACCACCACTTTCAGCAGTGCGAAGACCATGCGGCG
 ACCTTAAAAACCTTTTCGGCTTCGGCCCTGAATTGTTTAAACTCAGGAGGCACCCTCGTG
 GTGAAGTCCTATGGCTACGCCGACCGCAACAGTGAGGACGTAGTCACCGCTCTTGCCAGA
 AAGTTTGTCAAGGTGTCTGCAGCGAGACCAGATTGTGTCTCAAGCAATACAGAAATGTAC
 CTGATTTTCCGACAACCTAGACAACAGCCGTACACGGCAATTCACCCCGCACCATCTGAAT
 TGCGTGATTTTCGTCCGTGTATGAGGGTACAAGAGATGGAGTTGGAGCCGCGCCGTACATC
 CGCACAAAAGGGAGAATATTGCTGACTGTCAAGAGGAAGCAGTTGTCAACGCAAGCCAAAT
 CCGCTGGGTAGACCAGGCGAAGGAGTCTGCCGTGCCATCTATAAACGTTGGCCGACCAGT
 TTTACCGATTTCAGCCACGGAGACAGGCACCGCAAGAATGACTGTGTGCCTAGGAAAGAAA
 GTGATCCACGCGGTTCGGCCCTGATTTCCGGAAGCACCCAGAAGCAGAAGCCTTGAAATTG
 CTACAAAACGCCTACCATGCAGTGGCAGACTTAGTAAATGAACATAACATCAAGTCTGTC
 GCCATTCACCTGCTATCTACAGGCATTTACGCAGCCGGAAAAGACCGCCTTGAAGTATCA
 CTTAAGTGTGACAACCGCGCTAGACAGAACTGACGCGGACGTAACCATCTATTGCCTG
 GATAAGAAAGTGAAGGAAAGAATCGACGCGGCACTCCAACCTTAAGGAGTCTGTAACAGAG
 CTGAAGGATGAAGATATGGAGATCGACGATGAGTTAGTATGGATTTCATCCAGCAAGTTGC
 TTGAAGGGAAGAAAGGGATTTCAGTACTACAAAAGGAAAATTGTATTTCGTACTTCGAAGGC
 ACCAAATTCCATCAAGCAGCAAAAAGACATGGCGGAGATAAAGGTCCTGTTCCCTAATGAC
 CAGGAAAGTAATGAACAACCTGTGTGCCTACATATTGGGTGAGACCATGGAAGCAATCCGC
 GAAAAGTGCCCGGTGACCATAAACCGTCTGCTAGCCCGCCCAAAACGTTGCCGTGCCTT
 TGCATGTATGCCATGACGCCAGAAAGGGTCCACAGACTTAGAAGCAATAACGTCAAAGAA
 GTTACAGTATGCTCCTCCACCCCTTCTTAAGCACAAAATTGAAGATGTTTCAAGAGTTT
 CAGTGCACGAAAGTAGTCTGTTTAAATCCGACACTCCCGCATTTCGTTCCCGCCGTAAAG
 TACATAGAAGTGCCAGAACAGCCTACCGCTCCTCTGCACAGGCCGAGGAGGCCCCCGAA
 GTTGTAGCGACACCGTCACCATCTACAGCTGATAACACCTCGCTTGATGTACAGACATC
 TCACTGGATATGGATGACAGTAGCGAAGGCTCACTTTTTTCGAGCTTTAGCGGATCGGAC
 AACTCTATTACTAGTATGGACAGTTGGTCGTCAAGGACCTAGTTCACTAGAGATAGTAGAC
 CGAAGGCAGGTGGTGGTGGCTGACGTTTCATGCCGTCCAAGAGCCTGCCCTATTCCACCG
 CCAAGGCTAAAGAAGATGGCCCGCTGCGAGCGGCAAGAAAAGAGCCCACTCCACCGGCA
 AGCAATGACTCTGAGTCCCTCCACCTCTTTTGGTGGGTATCCATGTCCCTCGGATCA
 ATTTTCGACGGAGAGACGGCCCGCAGGCGAGCGGTACAACCCCTGGCAACAGGCCCCACG
 GATGTGCCTATGTCTTTCGGATCGTTTTCCGACGGAGAGATTGATGAGCTGAGCCGAGA
 GTAAGTGAAGTCCGAACCCGTCTGTTTGGATCATTTGAACCGGGCGAAGTGAAGTCAATT
 ATATCGTCCCGATCAGCCGTATCTTTTCTCTACGCAAGCAGAGACGTAGACGCAGGAGC
 AGGAGGACTGAATACTGACTAACCGGGGTAGGTGGGTACATATTTTCGACGGACACAGGC
 CCTGGGCACTTGCAAAAAGAAGTCCGTTCTGCAGAACCAAGCTTACAGAACCGACCTTGGAG
 CGAATGTCTGGAAGAATTTCATGCCCGGTGCTCGACACGTCGAAAGAGGAACAACCTC
 AAACCTCAGGTACAGATGATGCCACCGAAGCCAAACAAAAGTAGGTACCACTCTCGTAAA
 GTAGAAAATCAGAAAGCCATAACCACTGAGCGACTACTGTCAAGGACTACGACTGTATAAC
 TCTGCCACAGATCAGCCAGAATGCTATAAGATCACCTATCCGAAACCAATTGTAAGTCCAGT
 AGCGTACCGGCGAAGTACTCCGATCCACAGTTTCGCTGTAGCTGTCTGTAACAACCTATCTG
 CATGAGAACTATCCGACAGTAGCATCTTATCAGATTACTGACGAGTACGATGCTTACTTG
 GATATGGTAGACGAGACAGTCGCATGCCTGGTACTGCAACCTTCTGCCCGCTAAGCTT
 AGAAGTTACCCGAAAAAACATGAGTATAGAGCCCCGAATATCCGCAGTGCGGTTCCATCA

GCGATGCAGAACACGCTACAAAATGTGCTCATTGCCGCAACTAAAAGAAATTGCAACGTC
 ACGCAGATGCGTGAACCTGCCAACACTGGACTCAGCGACATTCAATGTGCAATGCTTTTCGA
 AAATATGCATGTAATGACGAGTATTGGGAGGAGTTTCGCTCGGAAGCCAATTAGGATTACC
 ACTGAGTTTGTACCGCATATGTAGCTAGACTGAAAGGCCCTAAGGCCGCCGCACTATTT
 GCAAAGACGTATAATTTGGTCCCATTGCAAGAAGTGCCTATGGATAGATTTCGTCATGGAC
 ATGAAAAGAGACGTGAAAGTTACACCAGGCACGAAACACACAGAAGAAAGACCGGAAAGTA
 CAAGTGATACAAGCCGCAGAACCCCTGGCGACTGCTTACTTATGCGGGATTACACCGGGAA
 TTAGTGCGTAGGCTTACGGCCGTCTTGCTTCCAAACATTACACGCTTTTTTGACATGTCG
 GCGGAGGATTTTGATGCAATCATAGCAGAACACTTCAAGCAAGGCGACCCGGTACTGGAG
 ACGGATATCGCATCATTCGACAAAAGCCAAGACGACGCTATGGCGTTAACCCGGTCTGATG
 ATCTTGAGGACCTGGGTGTGGATCAACCACTACTCGACTTGATCGAGTGCGCCTTTGGA
 GAAATATCATCCACCCATCTACCTACGGGTACTCGTTTTAAATTTCGGGGCGATGATGAAA
 TCCGGAATGTTCTCACACTTTTTGTCAACACAGTTTTGAATGTCGTTATCGCCAGCAGA
 GTACTAGAAGAGCGGCTTAAAACGTCCAGATGTGCAGCGTTTATTGGCGACGACAACATC
 ATACATGGAGTAGTATCTGACAAAGAAATGGCTGAGAGGTGCGCCACCTGGCTCAACATG
 GAGGTTAAGATCATCGACGAGTATCGGTGAGAGACCACCTTACTTCTGCGGCGGATTT
 ATCTTGCAAGATTTCGTTTACTTCCACAGCGTGGCGGATCCCTGAAAAGGCTG
 TTTAAGTTGGGTAAACCGCTCCAGCCGACGACGAGCAAGACGAAGACAGAAGACGCGCT
 CTGCTAGATGAAACAAAGGCGTGGTTTAGAGTAGGTATAACAGGCACTTTAGCAGTGGCC
 GTGACGACCCGGTATGAGGTAGACAATATTACACCTGTCCTACTGGCATTGAGAACTTTT
 GCCCAGAGCAAAAGAGCATTCCAAGCCATCAGAGGGGAAATAAAGCATCTCTACGGTGGT
 CCTAAATAGTCAGCATAGTACATTTTCATCTGACTAATACCACAACACCACCACCTCTAGA
 TTAATTAACCTGAGGCGCGCCGGGCCAGAGGATCTTTGTGAAGGAACCTTACTTCTGTG
 GTGTGACATAAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAAT
 TTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCAA
 CCTATGGAAGTATGAAATGGGAGCAGTGGTGGAATGCCTTTAATGAGGAAAACCTGTTTT
 GCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCTGACTCTCAACATTCTACTC
 CTCCAAAAAGAGAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTT
 TTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACACCACAA
 AGGAAAAAGCTGCATGCTATACAAGAAAAATATGGAATAATTTGATGTAGCGGCCCA
 ATGATCCGACCAAGTCAAAACTCGATGTACTTCCGAGGAACTGATGTGCATAATGAGCAG
 CTGGTACATTAGATCCCCGCTTACCGCGGGCAATATAGCAACACTAAAACTCGATGTAC
 TTCCGAGGAAGCGCAGTGCATAATGCTGCGCAGTGTGCCACATAACCACTATATTAACC
 ATTTATCTAGCGGACGCCAAAAACTCAATGTATTTCTGAGGAAGCGTGGTGCATAATGCC
 ACGCAGCGTCTGCATAACTTTTATTATTTCTTTTATTAATCAACAAAATTTTGTTTTTAA
 CATTTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGGAATTCCCAACTTGTTTTAT
 TGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAAGCATT
 TTTTCTGATTCTAGTTGTGGTTTGTCTTCCAAACTCATCAATGTATCTTATCATGTCTG
 GATCCGTCGAGACGCGTGCAGGCCGCGGGAATTCGATCTTTATGTGTAACTCTTGCTGAA
 GCTCTTACACCAATGCTGGGGGACATGTACCTCCCAGGGGCCAGGAAGACTACGGGAGG
 CTACACCAACGTCAATCAGAGGGGCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGG
 CATTAGCAATAGTGTATATAAGGCCCTTGTTAACCTAAACGGGTAGCATATGCTTCC
 CGGGTAGTAGTATATACTATCCAGACTAACCTAATTCAATAGCATATGTTACCCAACGG
 GAAGCATATGCTATCGAATTAGGGTTAGTAAAGGGTCTTAAGGAACAGCGATATCTCCC
 ACCCATGAGCTGTACGGTTTTTATTACATGGGGTCAAGGATTCACGAGGGTAGTGAAC
 CATTTTAGTCAAGGGCAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACCTCTCTGAAT
 CTTCGCTGCTTCTTCATTCTCTTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAAC
 AGTAAGGTGTATGTGAGGTGCTCGAAAACAAGTTTCAGGTGACGCCCCCAGAATAAAAT
 TTGGACGGGGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCTCACAAACCC
 CTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCTGAATATCTTTAACAATAGAAT
 CCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCTCACACGAATTTATGGCTAT
 GGGCAACACATAATCCTAGTGCAATATGATACTGGGGTTATTAAGATGTGTCCCAGGCAG
 GGACCAAGACAGGTGAACCATGTTGTTTACACTTATTTGTAACAAGGGGAAAGAGAGTGG
 ACGCCGACAGCAGCGGACTCCACTGGTTGTCTTAACACCCCCGAAAATTAACGGGGCT
 CCACGCCAATGGGGCCCATAAACAAAGACAAGTGGCCACTCTTTTTTTTGAATTTGTGGA
 GTGGGGGCACGCGTCAGCCCCACACGCGCCCTGCGGTTTTGGACTGTAAATAAGGGT
 GTAATAACTTGGCTGATTGTAAACCCCGCTAACCACTGCGGTCAAACCACTTGCCCAAAA
 ACCACTAATGGCACCCCGGGGAATACCTGCATAAGTAGGTGGGCGGGCCAAGATAGGGGC
 GCGATTGCTCGCATCTGGAGGACAAATTACACACACTTGGCCTGAGCGCCAAGCACAGG
 GTTGTGGTCTCATATTACAGAGGTGCTGAGAGCACGGTGGGCTAATGTTGCCATGGG

TAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGC
 ATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGT
 ATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGC
 ATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGC
 ATATGCTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGC
 ATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATAT
 GCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATAT
 GCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAG
 GCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATAT
 GCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTCATGCATATACAGTCAGCATAT
 GATACCCAGTAGTAGAGTGGGAGTGCTATCCTTTGCATATGCCGCCACCTCCCAAGGGGG
 CGTGAATTTTCGCTGCTTGTCTTTTCTGTCATGCATCACTAGTGAATTCGCGGCCGCGT
 TAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAAGTATGCAAAGCATGCATCTCA
 ATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAAGTATGCAAA
 GCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGCCCATCCCGCCCC
 TAACTCCGCCCAGTTCGCCCCATTCTCCGCCCATGGCTGACTAATTTTTTTTATTTATG
 CAGAGCCGAGCCGCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTG
 GAGGCCTAGGCTTTTGCAAAAAGCTTGCTATGCCTGCAGGTCGCGCCGCCACGACCGGTGCC
 GCCACCATCCCTGACCCACGCCCTGACCCCTCACAAGGAGACGACCTTCCATGACCGA
 GTACAAGCCCACGGTGCCTCGCCACCCGCGACGACGTCCCCCGGGCCGTACGCACCCT
 CGCCGCCGCGTTCGCCGACTACCCGCCACGCGCCACACCGTCGACCCGGACCGCCACAT
 CGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAA
 GGTGTGGGTGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGA
 AGCGGGGCGGTGTTCCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGT
 GCCGCGCAGCAACAGATGGAAGGCCTCTGCGCCGCAACCGGCCCAAGGAGCCCGCGTG
 GTTCCTGGCCACCGTCGGCGTCTCGCCCGACACCAGGGCAAGGGTCTGGGCAGCGCGT
 CGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGTGCCCGCCTTCTGGAGACCTC
 CGCGCCCCGCAACCTCCCTTCTACGAGCGGCTCGGCTTCAACGTCACCGCCGACGTGCA
 GGTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCTGACGCCCGCC
 CCACGACCCGCGAGCGCCGACCGAAAGGAGCGCACGACCCCATGGCTCCGACCGAAGCCA
 CCCGGGGCGGCCCGCCGACCCCGACCCCGAGGGCCCAACGACTCTAGCTAGAGG
 ATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCACAG
 CTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCA
 GCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTT
 TCACTGCATTCTAGTTGTGGTTTGTCCAACGCGTCGGTACCAGCTTTTGTTCCTTTAGT
 GAGGGTTAATTTTCGAGCTTGCGCTAATCATGGTTCATAGCTGTTTCCTGTGTGAAATTGTT
 ATCCGCTCACAAATCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTG
 CCTAATGAGTGAGCTAACTCACATTAATTGCGTTTCGCTCACTGCCCGCTTTCCAGTCGG
 GAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGCGGTTTGC
 GTATTGGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTGCTTCGGCTGC
 GCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATA
 ACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCG
 CGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCAAAAAATCGACGCT
 CAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTTCCCCCTGGAA
 GCTCCCTCGTGCGCTCTCCTGTTCCGACCTGCCGCTTACCGGATACCTGTCCGCTTTC
 TCCCTTCGGGAAGCGTGCGCTTTCTCATAGCTACGCTGATAGGTATCTCAGTTCCGGTG
 AGGTCGTTTCGCTCCAAGCTGGGCTGTGTGACGAACCCCCGTTACGCCGACCGCTGCG
 CCTTATCCGGTAACATCGTCTTGAGTCCAACCCGTAAGACACGACTTATCGCCACTGG
 CAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCT
 TGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGC
 TGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCG
 CTGGTAGCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTC
 AAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCAGTT
 AAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATTTAA
 AATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAAT
 GCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCC
 GACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTG
 CAATGATACCGCGAGACCCACGCTACCGGCTCCAGATTTATCAGCAATAAACCAGCCAG
 CCGGAAGGGCCGAGCGCAGAAAGTGGTCTGCAACTTTATCCGCCTCCATCCAGTCTATTA
 ATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCCGCAGTTAATAGTTTGCAGCAACGTTGTTG

CCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTTCAGCTCCG
GTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCT
CCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTA
TGGCAGCACTGCATAATTCTTCTTACTGTTCATGCCATCCGTAAGATGCTTTTCTGTGACTG
GTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCC
CGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTG
GAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGA
TGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTACCCAGCGTTTCTG
GGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAAT
GTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTC
TCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCA
CATTTCCCCGAAAAGTGCCAC

CTGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGA
 CCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCCTCCCTTCCTTCTCG
 CCACGTTCCGCCGCGGATCCGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAAT
 CAATATTGGCTATTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATAT
 TGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTA
 ATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGTTACATAACTTAC
 GGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGAC
 GTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTGACGTCAATGGGTGGAGTATTT
 ACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT
 TGACGTCAATGACGGTAAATGGCCCGCTGGCATATTATGCCAGTACATGACCTTATGGGA
 CTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTT
 TTGGCAGTACATCAATGGGCGTGGATAGCGGTTTACTCACGGGGATTTCCTCAAGTCTCCA
 CCCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCTCAAAATG
 TCGTAACTCCGCCCCATTGACGCAAAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTA
 TATAAGCAGAGCTCGTTTAGTGAACCGTATTGACGGCGTAGTACACACTATTGAATCAAA
 CAGCCGACCAATTGCACTACCATCACAATGGAGAAGCCAGTAGTAAACGTAGACGTAGAC
 CCCCAGTCCGTTTGTCTGTCGCAACTGCCGCAAAAGCTTCCCGCAATTTGAGGTAGTAGC
 CAGCAGGTCACCTCAAAATGACCATGCTAATGCCAGAGCATTTTCGCATCTGGCCAGTAAA
 CTAATCGAGCTGGAGGTTTCTACACAGCGACGATCTTGGACATAGGCAGCGCACCGGCT
 CGTAGAATGTTTTCCGAGCACCAGTATCATTGTGTCTGCCCCATGCGTAGTCCAGAAGAC
 CCGGACCGCATGATGAAATATGCCAGTAACTGGCGGAAAAAGCGTGCAAGATTACAAAC
 AAGAACTTGCATGAGAAGATTAAGGATCTCCGGACCGTACTTGATACGCCGGATGCTGAA
 ACACCATCGCTCTGCTTTCACAACGATGTTACCTGCAACATGCGTGCCGAATATTCGCT
 ATGCAGGACGTGTATATCAACGCTCCCGGAACATATCTATCATCAGGCTATGAAAGCGGTG
 CGGACCCGTGACTGGATTGGCTTCGACACCAACCCAGTTCATGTTCTCGGCTATGGCAGGT
 TCGTACCCTGCGTACAACACCAACTGGGCGGACGAGAAAAGTCTTGAAGCGCGTAACATC
 GGACTTTGCAGCACAAAGCTGAGTGAAGGTAGGACAGGAAAATTGTGATAATGAGGAAG
 AAGGAGTTGAAGCCCCGGGTGCGCGGTTTATTTCTCCGTAGGATCGACACTTTATCCAGAA
 CACAGAGCCAGCTTGCAGAGCTGGCATCTTCCATCGGTGTTCCACTTGAATGGAAAGCAG
 TCGTACACTTGGCGGTGTGATACAGTGGTGAAGTTCGAAGGCTACGTAGTGAAGAAAATC
 ACCACTGTCGCGGTGATACAGGAGAAACCGTGGGATACGCGGTTACACACAGCGAG
 GGCTTCTTGCTATGCAAAAGTTACTGACACAGTAAAAGGAGAACGGGTATCGTTCCCTGTG
 TGCACGTACATCCCGGCCACCATATGCGATCAGATGACTGGTATAATGGCCACGGATATA
 TCACCTGACGATGCACAAAACTTCTGGTTGGGCTCAACCAGCGAATTGTCATTAACGGT
 AGGACTAACAGGAACACCAACACCATGCAAAATTACCTTCTGCCGATCATAGCACAAGGG
 TTCAGCAAATGGGCTAAGGAGCGCAAGGATGATCTTGATAACGAGAAAATGCTGGGTACT
 AGAGAACGCAAGCTTACGTATGGCTGCTTGTGGGCGTTTCGCACTAAGAAAGTACATTCG
 TTTTATCGCCCACTGGAACGACGACCTGCGTGAAGTCCGAGCCTCTTTAGCGCTTTT
 CCCATGTCTGTCGATGACGACCTCTTTGCCATGTGCTGAGGCGAGAAATGAAACTG
 GCATTGCAACCAAGAAGGAGGAAAACTGCTGCAGGTCTCGGAGGAATTAGTCATGGAG
 GCCAAGGCTGCTTTTGAGGATGCTCAGGAGGAAGCCAGAGCGGAGAAGCTCCGAGAAGCA
 CTTCCACCATTAGTGGCAGACAAAGGCATCGAGGCAGCCGAGAAGTTGTCTGCGAAGTG
 GAGGGGCTCCAGGCGGACATCGGAGCAGCATTAGTTGAAACCCCGCGCGGTACGTAAGG
 ATAATACCTCAAGCAAATGACCGTATGATCGGACAGTATATCGTTGTCTCGCCAACTCT
 GTGCTGAAGAATGCCAACTCGCACGCGACCCGCTAGCAGATCAGGTAAAGATCAT
 ACACCTCCGGAAGATCAGGAAGGTACGCGGTGCAACCATAACGACGCTAAAGTACTGATG
 CCAGCAGGAGGTGCCGTACCATGGCCAGAATTCTAGCACTGAGTGAGAGCGCCACGTTA
 GTGTACAACGAAAGAGAGTTTGTGAACCGCAAACTATACCACATTGCCATGCATGGCCCC
 GCCAAGAATACAGAAGAGGAGCAGTACAAGGTTACAAAGGCAGAGCTTGACAGAAACAGAG
 TACGTGTTTGACGTGGACAAGAAGCGTTGCGTTAAGAAGGAAGAAGCCTCAGGTCTGGTC
 CTCTCGGGAGAAGTACCAACCCCTCCCTATCATGAGCTAGCTCTGGAGGGACTGAAGACC
 CGACTGCGGTCCCGTACAAGGTGCAACAAATAGGAGTGATAGGCACACCGGGGTGCGGC
 AAGTCAGCTATTATCAAGTCAACTGTACGGCAGCAGATCTTGTACCAGCGGAAAGAAA
 GAAAATTGTGCGGAAATTGAGGCCGACGTGCTAAGACTGAGGGGTATGCAGATTACGTG
 AAGACAGTAGATTGCGTTATGCTCAACGGATGCCACAAAGCCGTAGAAGTGCTGTACGTT
 GACGAAGCGTTGCGGTGCCACGAGGAGCACTACTTGCCTTGATTGCTATCGTCAGGCCC
 CGCAAGAAGGTAGTACTATGCGGAGACCCATGCAATGCGGATTCTTCAACATGATGCAA
 CTAAGGTACATTTCAATCACCTGAAAAAGACATATGCACCAAGACATTCTACAAGTAT
 ATCTCCCGGCGTTGCACACAGCCAGTTACAGCTATTGTATCGACACTGCATTACGATGGA
 AAGATGAAAACCAAGAACCCGTGCAAGAAGAATTGAAATCGATATTACAGGGGCCACA

AAGCCGAAGCCAGGGGATATCATCCTGACATGTTTCCGCGGGTGGGTAAAGCAATTGCAA
 ATCGACTATCCCGGACATGAAGTAATGACAGCCGCGCTCACAAGGGCTAACAGAAAA
 GGAGTGATGCCGTCCGGCAAAAAGTCAATGAAAACCCACTGTACGCGATCACATCAGAG
 CATGTGAACGTGTTGCTCACCCGCACTGAGGACAGGCTAGTGTGGAAAACCTTGAGGGC
 GACCCATGGATTAAGCAGCTACTAACATACCTAAAGGAACTTTCAGGCTACTATAGAG
 GACTGGGAAGCTGAACACAAGGGAATAATTGCTGCAATAAACAGCCCCACTCCCCGTGCC
 AATCCGTTCAGCTGCAAGACCAACGTTTGTGGGCGAAAGCATTGGAACCGATACTAGCC
 ACGGCCGGTATCGTACTTACCGGTTGCCAGTGGAGCGAACTGTTCCACAGTTTGCGGAT
 GACAAACCACATTCGGCCATTTACGCCTTAGACGTAATTTGCATTAAAGTTTTTCGGCATG
 GACTTGACAAGCGGACTGTTTTCTAAACAGAGCATCCCACTAACGTACCATCCCGCGAT
 TCAGCGAGGCCGGTAGCTCATTGGGACAACAGCCAGGAACCCGCAAGTATGGGTACGAT
 CACGCCATTGCCGCCGAACCTCTCCCGTAGATTTCCGGTGTTCAGCTAGCTGGGAAGGGC
 ACACAACCTGATTTGCAGACGGGGAGAACCAGAGTTATCTCTGCACAGCATAACCTGGTC
 CCGGTGAACCGCAATCTTCTCACGCCCTTAGTCCCCGAGTACAAGGAGAAGCAACCCGGC
 CCGGTCGAAAAATTTCTGAACCAAGTTCAAACACCACTCAGTACTTGTGGTATCAGAGGAA
 AAAATTGAAGCTCCCCGTAAGAGAATCGAATGGATCGCCCCGATTGGCATAGCCGGTGCA
 GATAAGAACTACAACCTGGCTTTCCGGTTTCCGCCGAGGCACGGTACGACCTGGTGTTC
 ATCAACATTGGAACATAAATACAGAAACCACTTTTCAGCAGTGCAGAACCATGCGGCG
 ACCTTAAAAACCCCTTTCGCGTTCCGGCCCTGAATTGTTTAAACTCAGGAGGCACCCCTCGTG
 GTGAAGTCTATGGCTACGCCGACCGCAACAGTGAGGACGTAGTCACCGCTCTTGCCAGA
 AAGTTTGTGAGGGTGTCTGCAGCGAGACCAGATTGTGTCTCAAGCAATACAGAAATGTAC
 CTGATTTTCCGCAACTAGACAACAGCCGTACACGGCAATTCACCCCGCACCATCTGAAT
 TGCGTGATTTTCGTCCGTGTATGAGGGTACAAGAGATGGAGTTGGAGCCGCGCCGTACATC
 CGCACAAAAGGGAGAAATATTGCTGACTGTCAAGAGGAAGCAGTTGTCAACGACGCCAAT
 CCGCTGGGTAGACCAGGCGAAGGAGTCTGCCGTGCCATCTATAAACGTTGGCCGACCAAT
 TTTACCGATTTCAGCCACGGAGACAGGCACCGCAAGAATGACTGTGTGCCTAGGAAAGAAA
 GTGATCCACGCGGTCCGCCCTGATTTCCGGAAGCACCCAGAAGCAGAAGCCTTGAAATTG
 CTACAAAACGCCTACCATGCAGTGGCAGACTTAGTAAATGAACATAACATCAAGTCTGTC
 GCCATTTCACTGCTATCTACAGGCATTTACGCAGCCGGAAGAGCCGCTTGAAGTATCA
 CTTAACTGCTTGACAACCGCGCTAGACAGAACTGACGCGGACGTAACCATCTATTGCCTG
 GATAAGAAAGTGAAGGAAGAAATCGACGCGGCACTCCAACCTAAGGAGTCTGTAAACAGAG
 CTGAAGGATGAAGATGAGAGTACGAGTACGAGTGTAGTATGGATTTCATCCAGGATTCG
 TTGAAGGGAAGAAAGGGATTTCAGTACTACAAAAGGAAAATTGTATTCGTACTTCGAAGGC
 ACCAAATTCCATCAAGCAGCAAAAGACATGGCGGAGATAAAGGTCCTGTTCCCTAATGAC
 CAGGAAAGTAATGAACAACCTGTGTGCCTACATAATTGGGTGAGACCATGGAAGCAATCCGC
 GAAAAGTGCCCGGTGACCATAAACCCGTGCTAGCCCGCCCAAAACGTTGCCGTGCCTT
 TGCATGTATGCCATGACGCCAGAAAGGGTCCACAGACTTAGAAGCAATAACGTCAAAGAA
 GTTACAGTATGCTCCTCCACCCCTTCTTAAGCACAAAATTAAGAATGTTTCAGAAAGTT
 CAGTGCACGAAAGTAGTCTCTGTTTAACTCCGACACTCCCGCATTCGTTCCCGCCGTAAG
 TACATAGAAGTGCCAGAACAGCCTACCGTCTCTCTGCACAGGCCGAGGAGGCCCCGAA
 GTTGTAGCGACACCGTCACCATCTACAGCTGATAACACCTCGCTTGATGTACAGACATC
 TCACTGGATATGGATGACAGTAGCGAAGGCTCACTTTTTTCGAGCTTTAGCGGATCGGAC
 AACTCTATTACTAGTATGGACAGTTGGTCTGACGACCTAGTTCACTAGAGATAGTAGAC
 CGAAGGCAGGTGGTGGTGGCTGACGTTTCATGCCGTCCAAGAGCCTGCCCTATTCCACCG
 CCAAGGCTAAAGAAGATGGCCCGCTGGCAGCGGCAAGAAAAGAGGCCACTCCACCGGCA
 AGCAATAGCTCTGAGTCCCTCCACCTCTCTTTTGGTGGGGTATCCATGTCCCTCGGATCA
 ATTTTCGACGGAGAGACCGGCCCGCCAGGACGCGTACAACCCCTGGCAACAGGCCCCACG
 GATGTGCCTATGTCTTTCGGATCGTTTTTCCGACGGAGAGATTGATGAGCTGAGCCGAGA
 GTAAGTGAAGTCCGAACCCGCTCTGTTTGGATCATTTGAACCGGGCGAAGTGAAGTCAATT
 ATATCGTCCCGATCAGCCGTATCTTTTCTCTACGCAAGCAGAGACGTAGACGCAGGAGC
 AGGAGGACTGAATACTGACTAACCGGGGTAGGTGGGTACATATTTTCGACGGACACAGGC
 CCTGGGCACTTGCAAAAAGAGTCCGTTCTGCAGAACCAAGCTTACAGAACCGACCTTGAG
 CGCAATGTCTGGAAAGATTATGCCCCGGTGCTCGACACGTCGAAAGAGGAACAACCTC
 AAACCTCAGGTACAGATGATGCCACCGAAGCCAACAAAAGTAGGTACAGTCTCGTAA
 GTAGAAAATCAGAAAGCCATAACCACTGAGCGACTACTGTACGACTACGACTGTATAAC
 TCTGCCACAGATCAGCCAGAATGCTATAAGATCACCTATCCGAAACCAATTGTAAGTCCAGT
 AGCGTACCGGCGAACTACTCCGATCCACAGTTTCGCTGTAGCTGTCTGTAAACACTATCTG
 CATGAGAACTATCCGACAGTAGCATCTTATCAGATTACTGACGAGTACGATGCTTACTTG
 GATATGGTAGACGAGACAGTCGATGCCTGGATACTGCAACCTTCTGCCCGCTAAGCTT
 AGAAGTTACCCGAAAAAACATGAGTATAGAGCCCCGAATATCCGCAGTGCGGTTCCATCA

Fig. 9B

GCGATGCAGAACACGCTACAAAATGTGCTCATTGCCGCACTAAAAGAAAATTGCAACGTC
 ACGCAGATGCGTGAACCTGCCAACACTGGACTCAGCGACATTCAATGTGCAATGCTTTGCA
 AAATATGCATGTAATGACGAGTATTGGGAGGAGTTCGCTCGGAAGCCAATTAGGATTACC
 ACTGAGTTTGTACCCGCATATGTAGCTAGACTGAAAGGCCCTAAGGCCGCCGCACTATTT
 GCAAAGACGTATAATTTGGTCCCATTGCAAGAAGTGCCTATGGATAGATTGCTCATGGAC
 ATGAAAAGAGACGTGAAAGTTACACCAGGCACGAAACACACAGAAGAAAAGACCGAAAAGTA
 CAAGTGATACAAGCCGCAGAACCCCTGGCGACTGCTTACTTATGCGGGATTACCCGGGAA
 TTAGTGCGTAGGCTTACGGCCGTCTTGCTTCCAAACATTACACGCTTTTTGACATGTCG
 GCGGAGGATTTTGTATGCAATCATAGCAGAACACTTCAAGCAAGGCCGACCCGGTACTGGAG
 ACGGATATCGCATTCATTCGACAAAAGCCAAGACGACGCTATGGCGTTAACC GGTTCTGATG
 ATCTTGAGGACCTGGGTGTGGATCAACCACTACTCGACTTGATCGAGTGC GCCTTTGGA
 GAAATATCATCCACCCATCTACCTACGGGTACTCGTTTTAAATTGCGGGCGATGATGAAA
 TCCGGAATGTTCTCACA CTTTTGTCAACACAGTTTTGAATGTCGTTATCGCCAGCAGA
 GTACTAGAAGAGCGGCTTAAACGTTCCAGATGTGCAGCGTTTATTGGCGACGACAACATC
 ATACATGGAGTAGTATCTGACAAAGAAATGGCTGAGAGGTGCGCCACCTGGCTCAACATG
 GAGGTAAAGATCATCGACGCAGTCATCGGTGAGAGACCCTTACTTCTGCGCGGATTT
 ATCTTGCAAGATTGCGTTACTTCCACAGCGTGGCGGTGGCGGATCCCTGAAAAGGCTG
 TTTAAGTTGGGTAAACCGCTCCAGCCGACGACGAGCAAGACGAAGACAGAAGACGCGCT
 CTGCTAGATGAAACAAAGGCGTGGTTTAGAGTAGGTATAACAGGCACTTTAGCAGTGGCC
 GTGACGACCCGGTATGAGGTAGACAATATTACACCTGTCTACTGGCATTGAGAACTTT
 GCCCAGAGCAAAAGAGCATTCCAAGCCATCAGAGGGGAAATAAAGCATCTCTACGGTGGT
 CCTAAATAGTCAGCATAGTACATTTCTGACTAATACCACAACACCACCCTCTAGA
 TTAATTAACCTCGAGGCGCGCCGGGCCAGAGGATCTTTGTGAAGGAACCTTACTTCTGTG
 GTGTGACATAATTGGACAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAAT
 TTTAAGTGATAATGTGTAAACTACTGATTCTAATTGTTTGTGATTTTAGATTCCAA
 CCTATGGAAGTATGAATGGGAGCAGTGGTGGAAATGCCTTTAATGAGGAAAACCTGTTTT
 GCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCTGACTCTCAACATTCTACTC
 CTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTT
 TTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACACCACAA
 AGGAAAAAGCTGCACTGCTATACAAGAAATTTATGAAAAAATATTTGATGTAGCGGCCCA
 ATGATCCGACCAGCAAAACTCGATGTATTTCCGAGGAAGTATGTGCATAATGCATCAGG
 CTGGTACATTAGATCCCGCTTACCGCGGGCAATATAGCAACACTAAAAACTCGATGTAC
 TTCCGAGGAAGCGCAGTGCATAATGCTGCGCAGTGTGCCACATAACCACTATATTAACC
 ATTTATCTAGCGGACGCCAAAAACTCAATGTATTTCTGAGGAAGCGTGGTGCATAATGCC
 ACGCAGCGTCTGCATAACTTTTATTATTTCTTTTATTAATCAACAAAATTTTGTTTTTAA
 CATTTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGGAATTCCCAACTTGTTAT
 TGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATT
 TTTTCTACTGCATTCTAGTTGTGGTTTGTTCCAAACTCATCAATGTATCTTATCATGTCTG
 GATCCGTGAGACGCGTGGCGCCGCGGAAATTCGATGTGGCTTTCATCCTGGAGCAGACT
 TTGGAGTCTGTGGACTGCAACACAACATTGCCTTTATGTGTAACCTCTGGCTGAAGCTCT
 TACACCAATGCTGGGGGACATGTACCTCCCAGGGGGCCAGGAAGACTACGGGAGGCTACA
 CCAACGTCAATCAGAGGGGCCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATT
 GCAATAGTGTATAAAGGCCCCCTTGTTAACCTAAACGGGTAGCATATGCTTCCCGGGT
 AGTAGTATATACTATCCAGACTAACCCTAATTCAATAGCATATGTTACCCAACGGGAAGC
 ATATGCTATCGAATTAGGGTAGTAAAGGGTCTAAGGAACAGCGATATCTCCACCCC
 ATGAGCTGTACGGTTTTTATTACATGGGGTCCGAGGATTCCACGAGGGTAGTGAACCATTT
 TAGTCACAAGGGCAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACCTCTCTGAATCTTCG
 CCTGCTTCTTCACTCTCTCTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAA
 GGTGTATGTGAGGTGCTCGAAAACAAGTTTCAGGTGACGCCCCCAGAATAAAATTTGGA
 CGGGGGGTTCAAGTGGTGGCATTGTGCTATGACACCAATATAACCCTCACAAACCCCTTGG
 GCAATAAACTAGTGTAGGAATGAAACATTCTGAATATCTTTAACAATAGAAATCCATG
 GGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCTCACACGAATTTATGGCTATGGGCA
 ACACATAATCTAGTGCAATATGATACTGGGTTATTAAGATGTGTCCAGGCAGGGACC
 AAGACAGGTGAACCATGTTGTTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCC
 GACAGCAGCGGACTCCACTGGTTGTCTTAACACCCCCGAAAATTAACGGGGCTCCACG
 CCAATGGGGGCCATAAACAAGACAAGTGGCCACTCTTTTTTTTGAATTTGTGGAGTGGG
 GGCACGCGTCAGCCCCCACACGCGCCCTGCGGTTTTGGACTGTAAAATAAGGGTGTAAAT
 AACTTGGCTGATTGTAAACCCCGCTAACCACTGCGGTCAAACCACTTGCCCAAAAACCAC
 TAATGGCACCCCGGGGAATACCTGCATAAGTAGGTGGGCGGGCCAAGATAGGGGGCGCGAT
 TGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAGCGCCAAGCACAGGGTTGT

[illegible]

Fig. 9D

GCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGA
 GCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCCTAGGCTTTTGCAAAAAGCTTGC
 ATGCCTGCAGGTGCGCCGCCACGACCGGTGCGGCCACCATCCCTGACCCACGCCCTGA
 CCCCTCACAAGGAGACGACCTTCCATGACCGAGTACAAGCCCACGGTGCGCTCGCCACC
 CGCGACGACGTCCCCCGGGCCGTACGCACCCTCGCGCCGCGTTTCGCCGACTACCCGCC
 ACGCGCCACACCGTCGACCCGACCGCCACATCGAGCGGGTCAACGAGCTGCAAGAACTC
 TTCCTCACGCGCTCGGGCTCGACATCGGCAAGGTGTGGGTTCGCGGACGACGGCGCCCG
 GTGGCGGTCTGGACCACGCCGAGAGCGTCAAGCGGGGCGGTGTTCGCCGAGATCGGC
 CCGCGCATGGCCGAGTTGAGCGGTTCCCGGTGGCCGCGCAGCAACAGATGGAAGGCCTC
 CTGGCGCCGACCCGGCCAAAGGAGCCCGCTGGTTCCTGGCCACCGTCGGCGTCTCGCC
 GACCACCAAGGCAAGGTCTGGGACGCGCGCTCGTGCTCCCGGAGTGAGGAGCGCCGAG
 CGCGCCGGGTGCCCCGCTTCTGGAGACCTCCGCGCCCCGCAACCTCCCTTCTACGAG
 CGGCTCGGCTTCAACGTCACCGCCGACGTGAGGTGCCGAAGGACCGCGCACCTGGTGC
 ATGACCCGCAAGCCCGGTGCCTGACGCGCGCCACGACCCGCGAGCGCCCGACCGAAAGG
 AGCGCACGACCCCATGGCTCCGACCGAAGCCACCCGGGGCGGCCCGCGACCCCGCACCC
 CGCCCCGAGGCCACCGACTCTAGCTAGAGGATCATAATCAGCCATACCACATTTGTAG
 AGGTTTTACTTGCTTTAAAAAACCTCCACACCTCCCTGAACTGAAACATAAAATGA
 ATGCAATTGTTGTTAACTTGTATTGACGCTTATAATGGTTACAAATAAAGCAATA
 GCATCACAAATTTACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCA
 ACGCGTCGGTACCAGCTTTTGTCCCTTTAGTGAGGGTTAATTCGAGCTTGGCGTAATC
 ATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACG
 AGCCGGAAGCATAAAGTGTAAGGCCTGGGGTGCTAATGAGTGAGCTAACTCACATTAAT
 TGCGTTTCGCTCACTGCCCCGCTTTCAGTCCGGAAACCTGTCGTGCCAGCTGCATTAATG
 AATCGGCCAACGCGCGGGGAGAGGCGGTTTGCCTATTGGGCGCTCTTCCGCTTCTCGCT
 CACTGACTCGCTGCGCTCGGTCTGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGC
 GGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGG
 CCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCG
 CCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGG
 ACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGAC
 CTTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGCGCTTTCTCA
 TAGCTCACGCTGATAGGTATCTCAGTTCCGTGTAGGTGCTTCCGCTCCAAGCTGGGCTGTG
 GCACGAACCCCGTTACGCCGACCGCTTATCCGGTAACCTATCGCTTTCGAGTC
 CAACCCGGTAAGACACGACTTATCGCCACTGCCAGCAGCCACTGGTAACAGGATTAGCAG
 AGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACAC
 TAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGT
 TGGTAGCTCTTGATCCGGCAAACAAACACCGCTGGTAGCGGTGGTTTTTTTGTGTGCAA
 GCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGG
 GTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAA
 AAGGATCTTCACCTAGATCCTTTTAAATTAATAAAGTGTAAATCAATCTAAAGTAT
 ATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGC
 GATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGAT
 ACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACC
 GGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCC
 TGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAG
 TTCGCCAGTTAATAGTTTTCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACG
 CTCGTCGTTTGGTATGGCTTCATTACGCTCCGTTTCCCAACGATCAAGGCGAGTTACATG
 ATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTGTCAGAAG
 TAAGTTGGCCGCGAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGT
 CATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGA
 ATAGTGATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCC
 ACATAGCAGAACTTTAAAGTGCTCATATTGGAACGTTCTTCGGGGCGAAAACTCTC
 AAGGATCTTACCGCTGTTGAGATCCAGTTCCGATGTAACCCACTCGTGACCCCACTGATC
 TTCAGCATCTTTTACTTTACCAGCGTTTCTGGGTGAGCAAAAAACAGGAAGGCAAAATGC
 CGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTTCTCTTTTCA
 ATATTGTAAGCATTTATCAGGTTATTGTTCTCATGAGCGGATACATATTTGAATGTAT
 TTAGAAAAATAACAAATAGGGGTTCCGCGCACATTTCCCGAAAAAGTGCCAC

Fig. 9E